<SEC-DOCUMENT>0001104659-22-117755.txt : 20221114
<SEC-HEADER>0001104659-22-117755.hdr.sgml : 20221114
<ACCEPTANCE-DATETIME>20221114080017
ACCESSION NUMBER:		0001104659-22-117755
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20221110
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221114
DATE AS OF CHANGE:		20221114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COGNITION THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001455365
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40886
		FILM NUMBER:		221380403

	BUSINESS ADDRESS:	
		STREET 1:		2403 SIDNEY STREET
		STREET 2:		SUITE 261
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15203
		BUSINESS PHONE:		412-481-2210

	MAIL ADDRESS:	
		STREET 1:		2500 WESTCHESTER AVE
		CITY:			PURCHASE
		STATE:			NY
		ZIP:			10577

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COGNITION THERAPUTICS INC
		DATE OF NAME CHANGE:	20090204
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2230367d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:cgtx="http://cogrx.com/20221110">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_cgtx_cogrx.com_20221110 -->
<!-- Field: Set; Name: xdx; ID: xdx_045_20221110_20221110 -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DEntityCentralIndexKey_0001455365 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-11-10to2022-11-10" name="dei:EntityCentralIndexKey">0001455365</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-11-10to2022-11-10" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cgtx-20221110.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-11-10to2022-11-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-10</xbrli:startDate>
        <xbrli:endDate>2022-11-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>UNITED
STATES<br />
SECURITIES AND EXCHANGE COMMISSION<br />
</b></span><b>Washington, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_90B_edei--DocumentType_c20221110__20221110_z7Y7uk0oRWx8"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT<br />
Pursuant to Section&#160;13 or 15(d)<br />
of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event
reported):&#160;<b><span id="xdx_903_edei--DocumentPeriodEndDate_c20221110__20221110_z3GXq6GFIe76"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">November 10, 2022</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b><span id="xdx_901_edei--EntityRegistrantName_c20221110__20221110_zdzyzwEqukJi"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" name="dei:EntityRegistrantName">Cognition
Therapeutics,&#160;Inc.</ix:nonNumeric></span><br />
</b></span>(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 33%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20221110__20221110_zn19No21vQVb"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90E_edei--EntityFileNumber_c20221110__20221110_zKoD5yqKszng"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" name="dei:EntityFileNumber">001-40886</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 33%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20221110__20221110_zedcyvMPUVZ3"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" name="dei:EntityTaxIdentificationNumber">13-4365359</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction of<br />
incorporation or organization)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
File Number)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer<br />
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 46%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20221110__20221110_zST0w3gMa6Id"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" name="dei:EntityAddressAddressLine1">2500 Westchester Avenue</ix:nonNumeric></span><br />
<span id="xdx_90E_edei--EntityAddressCityOrTown_c20221110__20221110_zd1ZvV6Z8Gmj"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" name="dei:EntityAddressCityOrTown">Purchase</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20221110__20221110_z1yatVa8Wzva"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 10%">&#160;</td>
    <td style="vertical-align: bottom; width: 44%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_901_edei--EntityAddressPostalZipCode_c20221110__20221110_zcL5p2prbDee"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" name="dei:EntityAddressPostalZipCode">10577</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address of principal executive offices)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code:&#160;<b>(<span id="xdx_90C_edei--CityAreaCode_c20221110__20221110_zVlHAZRLppP2"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" name="dei:CityAreaCode">412</ix:nonNumeric></span>) <span id="xdx_90D_edei--LocalPhoneNumber_c20221110__20221110_zmWgKoJWLr23"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" name="dei:LocalPhoneNumber">481-2210</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Not
Applicable<br />
</b></span>(Former name or former address, if changed since last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.18in; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><span style="font-family: Wingdings"><span id="xdx_908_edei--WrittenCommunications_c20221110__20221110_zroTTqNfWkcl"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&#160;</td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><span style="font-family: Wingdings"><span id="xdx_90E_edei--SolicitingMaterial_c20221110__20221110_zeMNHLkay1Ch"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&#160;</td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><span style="font-family: Wingdings"><span id="xdx_90A_edei--PreCommencementTenderOffer_c20221110__20221110_zr4NV81K1IJd"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&#160;</td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><span style="font-family: Wingdings"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20221110__20221110_z5WYPE5GmZsg"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 31%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title of Each Class</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 31%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading Symbol</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 36%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name of Exchange on Which<br />
Registered</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_edei--Security12bTitle_c20221110__20221110_z67CS7ImLBK7"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span> </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--TradingSymbol_c20221110__20221110_zFWOpJBXujJj"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" name="dei:TradingSymbol">CGTX</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--SecurityExchangeName_c20221110__20221110_zTlADX3CBB48"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2
of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Emerging
growth company&#160;<span style="font-family: Wingdings"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20221110__20221110_zYZ3F71PfTP"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#120;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;<span style="font-family: Wingdings"><span id="xdx_90E_edei--EntityExTransitionPeriod_c20221110__20221110_zfaeJZ2baXf5"><ix:nonNumeric contextRef="From2022-11-10to2022-11-10" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>







<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 11%">Item 1.01</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">Entry into a Material Definitive Agreement.</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On November 10, 2022,
Cognition Therapeutics, Inc. (the &#8220;Company&#8221;) entered into an&#160;Underwriting&#160;Agreement&#160;(the &#8220;Underwriting&#160;Agreement&#8221;)
with Cantor Fitzgerald &amp; Co., as representative of the several underwriters named in Schedule A thereto (the &#8220;Underwriters&#8221;),
relating to the public offering (the &#8220;Offering&#8221;) of 5,000,000 shares of the Company&#8217;s common stock, $0.001 par value
per share (&#8220;Common Stock&#8221;), at a price to the public of $1.20 per share (the &#8220;Offering Price&#8221;), less underwriting
discounts and commissions. The Company also granted the Underwriters a&#160;30-day&#160;option to purchase up to an additional 750,000
shares of Common Stock at the Offering Price, less underwriting discounts and commissions. The net proceeds to the Company from the sale
of the shares of Common Stock, after deducting the underwriting discounts and commissions and other estimated offering related expenses
payable by the Company, will be approximately $5.4 million (or approximately $6.2 million if the Underwriters exercise in full their option
to purchase additional shares of Common Stock).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Offering was made
pursuant to the Company&#8217;s registration statement (the &#8220;Registration Statement&#8221;) on Form&#160;S-1&#160;(File&#160;No.
333-268228), filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on November 7, 2022, and declared effective by
the SEC on November 9, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In the&#160;Underwriting&#160;Agreement,
the Company made customary representations, warranties and covenants and also agreed to indemnify the Underwriter against certain liabilities,
including liabilities under the&#160;Securities Act of 1933, as amended, or to contribute to payments that the Underwriter may be required
to make because of such liabilities. The foregoing is only a brief description of the terms of the&#160;Underwriting&#160;Agreement, does
not purport to be a complete description of the rights and obligations of the parties thereunder, and is qualified in its entirety by
reference to the&#160;Underwriting&#160;Agreement, a copy of which is being filed as Exhibit 1.1 hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 11%"><span style="font-size: 10pt"><b>Item 2.02</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Results of Operations and Financial Condition.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529">On November
14, 2022, the Company issued a press release announcing its financial results for the quarter ended September 30, 2022. A copy of the
press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529">The information
disclosed under Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that
section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 11%"><span style="font-size: 10pt"><b>Item 8.01</b></span></td>
    <td><span style="font-size: 10pt"><b>Other Events. </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 10, 2022, the Company issued a press release announcing
the pricing of the Offering. A copy of the press release is filed herewith as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated
herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>





<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 11%">Item 9.01</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">Financial Statements and Exhibits.</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Exhibit<br />
No.</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Document</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: transparent">
    <td style="white-space: nowrap; vertical-align: top; width: 12%"><a href="tm2230367d1_ex1-1.htm"><span style="font-size: 10pt">1.1</span></a></td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 86%"><a href="tm2230367d1_ex1-1.htm"><span style="font-size: 10pt">Underwriting Agreement by and between Cognition Therapeutics,
    Inc. and Cantor Fitzgerald &amp; Co., dated November 10, 2022. </span></a></td></tr>
  <tr style="background-color: transparent">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt; color: #0000EE">&#160;</span></td></tr>
  <tr style="background-color: transparent">
    <td style="white-space: nowrap; vertical-align: top"><a href="tm2230367d1_ex99-1.htm"><span style="font-size: 10pt">99.1 </span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="tm2230367d1_ex99-1.htm"><span style="font-size: 10pt">Press Release, dated November 14, 2022</span></a></td></tr>
  <tr style="background-color: transparent">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: transparent">
    <td style="white-space: nowrap; vertical-align: top"><a href="tm2230367d1_ex99-2.htm"><span style="font-size: 10pt">99.2</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="tm2230367d1_ex99-2.htm"><span style="font-size: 10pt">Press Release, dated November 10, 2022.</span></a></td></tr>
  <tr style="background-color: transparent">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: transparent">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #212529"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 50%"><span style="font-size: 10pt; color: black"><b>COGNITION THERAPEUTICS, INC.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; width: 45%"><span style="font-size: 10pt"><i>/s/ Lisa Ricciardi</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Name:</span></td>
    <td><span style="font-size: 10pt">&#160;Lisa Ricciardi</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Title:</span></td>
    <td><span style="font-size: 10pt">&#160;President and Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">Date: November 14, 2022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"></span></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5ltpUitI3LSpiFSkivka7lWCbLZv4dyRvaWwRl4VlmflmhBiIJS10jQzHWZHDHpu2Vg6hwAoZzRm9I1utU/C3wIu2jpVx3fsDM/IMeiYJZXTyQme9a4tlClIO5WQYS4iSdDSG6UYEXz0jU+kSjdOqBmVK2DG1rNEpfvUJe/UkQ82rqzogW03Gx4VRL78hjmQMW7qrB/HVQp5nIhh0E4gl06391tysowbmNTa+y/bof4MPEEFJPA== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2230367d1_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 1.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>COGNITION
THERAPEUTICS,&nbsp;INC.</B></FONT><BR>
5,000,000 Shares of Common Stock&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(par value $0.001 per share)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Underwriting Agreement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">November&nbsp;10, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cantor Fitzgerald&nbsp;&amp; Co.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As Representative of the
several&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Underwriters listed in <U>Schedule
A&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Hereto</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">c/o Cantor Fitzgerald&nbsp;&amp; Co.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">499 Park Avenue&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cognition Therapeutics,&nbsp;Inc.,
a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), proposes to issue and sell to the several underwriters named in <U>Schedule
A</U> (the &ldquo;<B>Underwriters</B>&rdquo;) an aggregate of 5,000,000 shares (the &ldquo;<B>Firm Shares</B>&rdquo;) of its common stock,
par value $0.001 per share (&ldquo;<B>Common Stock</B>&rdquo;). In addition, the Company has granted to the Underwriters an option to
purchase up to an additional 750,000 shares of Common Stock, which are collectively called the &ldquo;<B>Option Shares</B>.&rdquo; The
Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the &ldquo;<B>Offered Shares.</B>&rdquo;
Cantor Fitzgerald&nbsp;&amp; Co. (&ldquo;<B>Cantor</B>&rdquo;) has agreed to act as representative of the several Underwriters (in such
capacity, the &ldquo;<B>Representative</B>&rdquo;) in connection with the offering and sale of the Offered Shares. To the extent there
are no additional underwriters listed on <U>Schedule A</U>, the term &ldquo;Representative&rdquo; as used herein shall mean Cantor, as
Underwriter, and the term &ldquo;Underwriters&rdquo; shall mean either the singular or the plural, as the context requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company has prepared and filed with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) a registration statement
on Form&nbsp;S-1, File No.&nbsp;333-268228. Such registration statement, as amended or supplemented, including the financial statements,
exhibits and schedules thereto, in the form in which it became effective under the Securities Act of 1933, and the rules&nbsp;and regulations
promulgated thereunder (collectively, the &ldquo;<B>Securities Act</B>&rdquo;), including all documents incorporated or deemed to be incorporated
by reference therein and any information deemed to be a part thereof at the time of effectiveness pursuant to Rule&nbsp;430A or 430B under
the Securities Act, is called the &ldquo;<B>Registration Statement</B>.&rdquo; Any registration statement filed by the Company pursuant
to Rule&nbsp;462(b)&nbsp;under the Securities Act in connection with the offer and sale of the Offered Shares is called the &ldquo;<B>Rule&nbsp;462(b)&nbsp;Registration
Statement</B>,&rdquo; and from and after the date and time of filing of any such Rule&nbsp;462(b)&nbsp;Registration Statement the term
 &ldquo;Registration Statement&rdquo; shall include the Rule&nbsp;462(b)&nbsp;Registration Statement. The preliminary prospectus dated
November&nbsp;7, 2022 describing the Offered Shares and the offering thereof is called the &ldquo;<B>Preliminary Prospectus</B>,&rdquo;
and the Preliminary Prospectus and </FONT>any other prospectus in preliminary form that describes the Offered Shares and the offering
thereof and is used prior to the filing of the Prospectus (as defined below) is called a &ldquo;<B>preliminary prospectus</B>.&rdquo;
As used herein, the term &ldquo;<B>Prospectus</B>&rdquo; shall mean the final prospectus in the form first used by the Underwriters to
confirm sales of the Offered Shares or in the form first made available to the Underwriters by the Company to meet requests of purchasers
pursuant to Rule&nbsp;173 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
used herein, &ldquo;<B>Applicable Time</B>&rdquo; is 7:30</FONT> a.m.&nbsp;(New York time) on November&nbsp;10, 2022. As used herein,
 &ldquo;<B>free writing prospectus</B>&rdquo; has the meaning set forth in Rule&nbsp;405 under the Securities Act, and &ldquo;<B>Time of
Sale Prospectus</B>&rdquo; means the Preliminary Prospectus, as amended or supplemented immediately prior to the Applicable Time, together
with the free writing prospectuses, if any, identified on <U>Schedule B</U> hereto and the pricing information set forth on <U>Schedule
C</U> hereto. As used herein, <B>&ldquo;Road Show&rdquo;</B> means a &ldquo;road show&rdquo; (as defined in Rule&nbsp;433 under the Securities
Act) relating to the offering of the Offered Shares contemplated hereby that is a &ldquo;written communication&rdquo; (as defined in Rule&nbsp;405
under the Securities Act). As used herein, &ldquo;<B>Section&nbsp;5(d)&nbsp;Written Communication</B>&rdquo; means each written communication
(within the meaning of Rule&nbsp;405 under the Securities Act) that is made in reliance on Section&nbsp;5(d)&nbsp;of the Securities Act
by the Company or any person authorized to act on behalf of the Company to one or more potential investors that are qualified institutional
buyers (&ldquo;<B>QIBs</B>&rdquo;) and/or institutions that are accredited investors (&ldquo;<B>IAIs</B>&rdquo;), as such terms are respectively
defined in Rule&nbsp;144A and Rule&nbsp;501(a)&nbsp;under the Securities Act, to determine whether such investors might have an interest
in the offering of the Offered Shares; &ldquo;<B>Section&nbsp;5(d)&nbsp;Oral Communication</B>&rdquo; means each oral communication, if
any, made in reliance on Section&nbsp;5(d)&nbsp;of the Securities Act by the Company or any person authorized to act on behalf of the
Company made to one or more QIBs and/or one or more IAIs to determine whether such investors might have an interest in the offering of
the Offered Shares; &ldquo;<B>Marketing Materials</B>&rdquo; means any materials or information provided to investors by, or with the
approval of, the Company in connection with the marketing of the offering of the Offered Shares, including any Road Show or investor presentations
made to investors by the Company (whether in person or electronically); and &ldquo;<B>Permitted Section&nbsp;5(d)&nbsp;Communication</B>&rdquo;
means the Section&nbsp;5(d)&nbsp;Written Communication(s)&nbsp;and Marketing Materials listed on <U>Schedule D</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All references in this Agreement
to financial statements and schedules and other information which are &ldquo;contained,&rdquo; &ldquo;included&rdquo; or &ldquo;stated&rdquo;
in, or &ldquo;part of&rdquo; the Registration Statement, the Rule&nbsp;462(b)&nbsp;Registration Statement, the Preliminary Prospectus,
any preliminary prospectus, the Time of Sale Prospectus or the Prospectus, and all other references of like import, shall be deemed to
mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by reference
in the Registration Statement, the Rule&nbsp;462(b)&nbsp;Registration Statement, the Preliminary Prospectus, any preliminary prospectus,
the Time of Sale Prospectus or the Prospectus, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All references in this Agreement
to amendments or supplements to the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Time of Sale Prospectus
or the Prospectus shall be deemed to mean and include the filing of any document under the Securities Exchange Act of 1934, as amended
and the rules&nbsp;and regulations promulgated thereunder (collectively, the &ldquo;<B>Exchange Act</B>&rdquo;), that is or is deemed
to be incorporated by reference in the Registration Statement, the Preliminary Prospectus, any preliminary prospectus or the Prospectus,
as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All references in this Agreement
to (i)&nbsp;the Registration Statement, the Preliminary Prospectus, any preliminary prospectus or the Prospectus, any amendments or supplements
to any of the foregoing, or any free writing prospectus, shall include any copy thereof filed with the Commission pursuant to its Electronic
Data Gathering, Analysis and Retrieval System (&ldquo;<B>EDGAR</B>&rdquo;) and (ii)&nbsp;the Prospectus shall be deemed to include any
 &ldquo;electronic Prospectus&rdquo; provided for use in connection with the offering of the Offered Shares as contemplated by Section&nbsp;3(n)&nbsp;below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that the Company
has only one subsidiary, then all references herein to &ldquo;subsidiaries&rdquo; of the Company shall be deemed to refer to such single
subsidiary, <U>mutatis mutandis</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company hereby confirms
its agreements with the Underwriters as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of the Company</U>. The Company represents and warrants to each Underwriter as of the date of this Agreement, the Applicable
Time, the First Closing Date (as hereinafter defined) and each Option Closing Date (as hereinafter defined), if any, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Compliance
with Registration Requirements</U>. The Registration Statement has become effective under the Securities Act. The Company has complied,
to the Commission&rsquo;s satisfaction, with all requests of the Commission for additional or supplemental information, if any. No stop
order suspending the effectiveness of the Registration Statement is in effect and no proceedings for such purpose have been instituted
or are pending or, to the best knowledge of the Company, are contemplated or threatened by the Commission. The documents incorporated
or deemed to be incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus, at the time they
were or hereafter are filed with the Commission, or became effective under the Exchange Act, as the case may be, complied and will comply
in all material respects with the requirements of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Disclosure</U>.
Each preliminary prospectus and the Prospectus when filed complied in all material respects with the Securities Act and, if filed by electronic
transmission pursuant to EDGAR, was identical (except as may be permitted by Regulation&nbsp;S-T under the Securities Act) to the copy
thereof delivered to the Underwriters for use in connection with the offer and sale of the Offered Shares. Each of the Registration Statement
and any post-effective amendment thereto, at the time it became or becomes effective and at all subsequent times, complied and will comply
in all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the Applicable Time, the
Time of Sale Prospectus did not, and at the First Closing Date and at each, if applicable, Option Closing Date (as defined in Section&nbsp;2),
the Time of Sale Prospectus, as then amended or supplemented by the Company, if applicable, will not, contain any untrue statement of
a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The Prospectus as of its date (as amended or supplemented) did not, and at the First Closing Date and
each, as applicable, Option Closing Date did not and will not contain any untrue statement of a material fact or omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.
The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from
the Registration Statement or any post-effective amendment thereto, or the Prospectus or the Time of Sale Prospectus, or any amendments
or supplements thereto, made in reliance upon and in conformity with written information relating to any Underwriter furnished to the
Company in writing by the Representative expressly for use therein, it being understood and agreed that the only such information consists
of the information described in Section&nbsp;9(b)&nbsp;below. There are no contracts or other documents required to be described in the
Time of Sale Prospectus or the Prospectus or to be filed as an exhibit to the Registration Statement which have not been described or
filed as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Free
Writing Prospectuses; Road Show</U>. As of the determination date referenced in Rule&nbsp;164(h)&nbsp;under the Securities Act, the Company
was not, is not or will not be (as applicable) an &ldquo;ineligible issuer&rdquo; in connection with the offering of the Offered Shares
pursuant to Rules&nbsp;164, 405 and 433 under the Securities Act. Each free writing prospectus that the Company is required to file pursuant
to Rule&nbsp;433(d)&nbsp;under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements
of the Securities Act. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule&nbsp;433(d)&nbsp;under
the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material
respects with the requirements of Rule&nbsp;433 under the Securities Act, including timely filing with the Commission or retention where
required and legending, and each such free writing prospectus, as of its issue date and at all subsequent times through the completion
of the public offer and sale of the Offered Shares did not, does not and will not include any information that conflicted, conflicts or
will conflict with the information contained in the Registration Statement, the Prospectus or any preliminary prospectus and not superseded
or modified. Except for the free writing prospectuses, if any, identified in <U>Schedule B</U>, and electronic road shows, if any, furnished
to the Representative before first use, the Company has not prepared, used or referred to, and will not, without the Representative&rsquo;s
prior written consent, prepare, use or refer to, any free writing prospectus. Each Road Show, when considered together with the Time of
Sale Prospectus, does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Emerging
Growth Company</U>. From the time of initial confidential submission of the Registration Statement to the Commission (or, if earlier,
the first date on which the Company engaged directly or through any person authorized to act on its behalf in any Section&nbsp;5(d)&nbsp;Written
Communication or Section&nbsp;5(d)&nbsp;Oral Communication) through the date hereof, the Company has been and is an &ldquo;emerging growth
company,&rdquo; as defined in Section&nbsp;2(a)&nbsp;of the Securities Act (an &ldquo;<B>Emerging Growth Company</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Testing-the-Waters
Materials</U>. The Company (i)&nbsp;has not alone engaged in any Section&nbsp;5(d)&nbsp;Written Communication or Section&nbsp;5(d)&nbsp;Oral
Communication other than Permitted Section&nbsp;5(d)&nbsp;Communications with the consent of the Representatives with entities that are
QIBs or IAIs and (ii)&nbsp;has not authorized anyone other than the Representatives to engage in such Permitted Section&nbsp;5(d)&nbsp;Communications.
The Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking Marketing Materials, Section&nbsp;5(d)&nbsp;Oral
Communications and Section&nbsp;5(d)&nbsp;Written Communications. The Company has not distributed or approved for distribution any Section&nbsp;5(d)&nbsp;Written
Communications other than those listed on <U>Schedule D</U> hereto. Any individual Permitted Section&nbsp;5(d)&nbsp;Communication does
not conflict with the information contained in the Registration Statement or the Time of Sale Prospectus, complied in all material respects
with the Securities Act, and when taken together with the Time of Sale Prospectus as of the Applicable Time, did not, and as of the First
Closing Date and as of each Option Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit
to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Distribution
of Offering Material By the Company</U>. Prior to the later of (i)&nbsp;the expiration or termination of the option granted to the several
Underwriters in &lrm;Section&nbsp;2 and (ii)&nbsp;the completion of the Underwriters&rsquo; distribution of the Offered Shares, the Company
has not distributed and will not distribute any offering material in connection with the offering and sale of the Offered Shares other
than the Registration Statement, the Time of Sale Prospectus, the Prospectus or any free writing prospectus reviewed and consented to
by the Representative, and the free writing prospectuses, if any, identified on <U>Schedule B</U> hereto and any Permitted Section&nbsp;5(d)&nbsp;Communications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Financial
Information</U>. The consolidated financial statements of the Company included or incorporated by reference in the Registration Statement,
the Time of Sale Prospectus and the Prospectus, if any, together with the related notes and schedules, present fairly, in all material
respects, the consolidated financial position of the Company and the Subsidiaries (as defined below) as of the dates indicated and the
consolidated results of operations, cash flows and changes in stockholders&rsquo; equity of the Company for the periods specified and
have been prepared in compliance with the requirements of the Securities Act and Exchange Act and in conformity with GAAP (as defined
below) applied on a consistent basis during the periods involved, except as may be expressly stated in the related notes thereto; there
are no financial statements (historical or pro forma) that are required to be included or incorporated by reference in the Registration
Statement, the Time of Sale Prospectus and the Prospectus that are not included or incorporated by reference as required; the Company
and the Subsidiaries (as defined below) do not have any material liabilities or obligations, direct or contingent (including any off-balance
sheet obligations), not described in the Registration Statement (excluding the exhibits thereto), the Time of Sale Prospectus and the
Prospectus; and all disclosures contained or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and
the Prospectus and the Issuer Free Writing Prospectuses, if any, regarding &ldquo;non-GAAP financial measures&rdquo; (as such term is
defined by the rules&nbsp;and regulations of the Commission) comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K
under the Securities Act, to the extent applicable. The interactive data in eXtensible Business Reporting Language included or incorporated
by reference in the Registration Statement and the Prospectus fairly presents the information called for in all material respects and
has been prepared in accordance with the Commission&rsquo;s rules&nbsp;and guidelines applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Conformity
with EDGAR Filing</U>. The Preliminary Prospectus and Final Prospectus delivered to the Underwriter for use in connection with the sale
of the Offered Shares pursuant to this Agreement will be identical to the versions of the Preliminary Prospectus and Final Prospectus
created to be transmitted to the Commission for filing via EDGAR, except to the extent permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Organization</U>.
The Company and each of its subsidiaries (as defined in Rule&nbsp;405 under the Securities Act) (&ldquo;<B>Subsidiaries</B>&rdquo;) are
duly organized, validly existing as a corporation and in good standing under the Laws of their respective jurisdictions of organization.
The Company and each of its Subsidiaries are duly licensed or qualified as a foreign corporation for transaction of business and in good
standing under the Laws of each other jurisdiction in which their respective ownership or lease of property or the conduct of their respective
businesses requires such license or qualification, and have all corporate power and authority necessary to own or hold their respective
properties and to conduct their respective businesses as described in the Registration Statement, the Time of Sale Prospectus and the
Prospectus, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or
in the aggregate, have a material adverse effect or would reasonably be expected to have a material adverse effect on or affecting the
assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders&rsquo; equity or results
of operations of the Company and the Subsidiaries taken as a whole, or prevent or materially interfere with the consummation of the transactions
contemplated hereby (a &ldquo;<B>Material Adverse Effect</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Subsidiaries</U>.
Except as set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, the Company has no subsidiary that
is a &quot;significant subsidiary&quot; of the Company within the meaning of Rule&nbsp;1.01 of Regulation S-X under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>No
Violation or Default</U>. Neither the Company nor any of its Subsidiaries is (i)&nbsp;in violation of its charter or by-laws or similar
organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both, would constitute
such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of
trust, loan agreement or other agreement or instrument to which the Company or any of its Subsidiaries is a party or by which the Company
or any of its Subsidiaries is bound or to which any of the property or assets of the Company or any of its Subsidiaries are subject; or
(iii)&nbsp;in violation of any Law of any Governmental Authority, except, in the case of each of clauses (ii)&nbsp;and (iii)&nbsp;above,
for any such violation or default that would not, individually or in the aggregate, have a Material Adverse Effect. To the Company&rsquo;s
knowledge, no other party under any material contract or other agreement to which it or any of its Subsidiaries is a party is in default
in any respect thereunder where such default would have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>No
Material Adverse Effect</U>. Subsequent to the respective dates as of which information is given in the Registration Statement, the Time
of Sale Prospectus, the Prospectus and the Free Writing Prospectuses, if any (including any document deemed incorporated by reference
therein), there has not been (i)&nbsp;any Material Adverse Effect or the occurrence of any development that the Company reasonably expects
will result in a Material Adverse Effect, (ii)&nbsp;any transaction which is material to the Company and the Subsidiaries taken as a whole,
(iii)&nbsp;any obligation or liability, direct or contingent (including any off-balance sheet obligations), incurred by the Company or
any Subsidiary, which is material to the Company and the Subsidiaries taken as a whole, (iv)&nbsp;any material change in the capital stock
or outstanding long-term indebtedness of the Company or any of its Subsidiaries or (v)&nbsp;any dividend or distribution of any kind declared,
paid or made on the capital stock of the Company or any Subsidiary, other than in each case above in the ordinary course of business or
as otherwise disclosed in the Registration Statement or Prospectus (including any document incorporated by reference therein).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Capitalization</U>.
The issued and outstanding shares of capital stock of the Company have been validly issued, are fully paid and nonassessable and, other
than as disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus, are not subject to any preemptive rights,
rights of first refusal or similar rights. The Company has an authorized, issued and outstanding capitalization as set forth in the Registration
Statement and the Prospectus as of the dates referred to therein (other than the grant of additional options under the Company&rsquo;s
existing stock option plans, or changes in the number of outstanding shares of Common Stock of the Company due to the issuance of shares
upon the exercise or conversion of securities exercisable for, or convertible into, Common Stock outstanding on the date hereof) and such
authorized capital stock conforms to the description thereof set forth in the Registration Statement, the Time of Sale Prospectus and
the Prospectus. The description of the securities of the Company in the Registration Statement, the Time of Sale Prospectus and the Prospectus
is complete and accurate in all material respects. Except as disclosed in or contemplated by the Registration Statement, the Time of Sale
Prospectus or the Prospectus, as of the date referred to therein, the Company does not have outstanding any options to purchase, or any
rights or warrants to subscribe for, or any securities or obligations convertible into, or exchangeable for, or any contracts or commitments
to issue or sell, any shares of capital stock or other securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Authorization;
Enforceability</U>. The Company has full legal right, power and authority to enter into this Agreement and perform the transactions contemplated
hereby. This Agreement has been duly authorized, executed and delivered by the Company and is a legal, valid and binding agreement of
the Company enforceable in accordance with its terms, except to the extent that enforceability may be limited by bankruptcy, insolvency,
reorganization, moratorium or similar Laws affecting creditors&rsquo; rights generally and by general equitable principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Authorization
of the Offered Shares</U>. The Offered Shares have been duly authorized for issuance and sale pursuant to this Agreement and, when issued
and delivered by the Company against payment therefor pursuant to this Agreement, will be duly and validly issued, fully paid and nonassessable,
free and clear of any pledge, lien, encumbrance, security interest or other claim, including any statutory or contractual preemptive rights,
resale rights, rights of first refusal or other similar rights, and will be registered pursuant to Section&nbsp;12 of the Exchange Act.
The Offered Shares, when issued, will conform to the description thereof set forth in or incorporated into the Registration Statement,
the Time of Sale Prospectus and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>No
Consents Required</U>. No consent, approval, authorization, order, registration or qualification of or with any Governmental Authority
is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale by the Company of the
Offered Shares, except for such consents, approvals, authorizations, orders and registrations or qualifications as may be required under
applicable state securities Laws or Laws of the Financial Industry Regulatory Authority Inc. (&ldquo;<B>FINRA</B>&rdquo;) or NASDAQ (as
defined below) in connection with the sale of the Offered Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>No
Preferential Rights</U>. Except as set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, (i)&nbsp;no
person, as such term is defined in Rule&nbsp;1-02 of Regulation S-X promulgated under the Securities Act (each, a &ldquo;<B>Person</B>&rdquo;),
has the right, contractual or otherwise, to cause the Company to issue or sell to such Person any Common Stock or shares of any other
capital stock or other securities of the Company, (ii)&nbsp;no Person has any preemptive rights, resale rights, rights of first refusal,
rights of co-sale, or any other rights (whether pursuant to a &ldquo;poison pill&rdquo; provision or otherwise) to purchase any Common
Stock or shares of any other capital stock or other securities of the Company, (iii)&nbsp; no Person has the right to act as an underwriter
or as a financial advisor to the Company in connection with the offer and sale of the Common Stock, and (iv)&nbsp;no Person has the right,
contractual or otherwise, to require the Company to register under the Securities Act any Common Stock or shares of any other capital
stock or other securities of the Company, or to include any such shares or other securities in the Registration Statement or the offering
contemplated thereby, whether as a result of the filing or effectiveness of the Registration Statement or the sale of the Offered Shares
as contemplated thereby or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Independent
Public Accounting Firm</U>. Ernst&nbsp;&amp; Young LLP (the &ldquo;<B>Accountant</B>&rdquo;), whose report on the consolidated financial
statements of the Company is filed with the Commission as part of the Company&rsquo;s most recent Annual Report on Form&nbsp;10-K filed
with the Commission and incorporated by reference into the Registration Statement and the Prospectus, are and, during the periods covered
by their report, were an independent registered public accounting firm within the meaning of the Securities Act and the Public Company
Accounting Oversight Board (United States). To the Company&rsquo;s knowledge, the Accountant is not in violation of the auditor independence
requirements of the Sarbanes-Oxley Act of 2002 (the &ldquo;<B>Sarbanes-Oxley Act</B>&rdquo;) with respect to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Enforceability
of Agreements</U>. All agreements between the Company and third parties expressly referenced in the Prospectus are legal, valid and binding
obligations of the Company enforceable in accordance with their respective terms, except to the extent that (i)&nbsp;enforceability may
be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors&rsquo; rights generally and by general
equitable principles and (ii)&nbsp;the indemnification provisions of certain agreements may be limited by federal or state securities
Laws or public policy considerations in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>No
Litigation</U>. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental proceeding pending
or, to the Company&rsquo;s knowledge, threatened against, or involving the Company or, to the Company&rsquo;s knowledge, any executive
officer or director that is required to be disclosed in the Time of Sale Prospectus, the Prospectus and the Registration Statement which
has not been disclosed therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Possession
of Licenses and Permits</U>. The Company (A)&nbsp;possesses the licenses, permits, certificates, authorizations, consents and approvals
(collectively, &quot;<B>Governmental Licenses</B>&quot;) issued by the appropriate governmental entities necessary to conduct its business
as currently conducted as described in the Time of Sale Prospectus, the Prospectus and the Registration Statement, and (B)&nbsp;has obtained
all necessary Governmental Licenses from other persons necessary to conduct its business, except, in each case of clauses (A)&nbsp;and
(B), (i)&nbsp;as described in the Time of Sale Prospectus, the Prospectus and the Registration Statement or (ii)&nbsp;to the extent that
any failure to possess any Governmental Licenses, provide any notice, make any filing, or obtain any Governmental Licenses would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; none of the Company and subsidiaries is in
violation of, or in default under, any Governmental License, except as would not reasonably be expected to have a Material Adverse Effect.
All of the Governmental Licenses are valid and in full force and effect, except when the invalidity of such Governmental Licenses or the
failure of such Governmental Licenses to be in full force and effect would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect. The Company has not received any notice of proceedings relating to the revocation or modification of
any Governmental Licenses which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would
have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Health
Care Authorizations</U>. The Company has submitted and possesses, or qualifies for applicable exemptions to, such valid and current registrations,
listings, approvals, clearances, licenses, certificates, authorizations or permits and supplements or amendments thereto (collectively,
 &ldquo;<B>Health Care Authorizations</B>&rdquo;) issued or required by the appropriate local, state, federal, national, supranational
or other foreign regulatory agencies or bodies (collectively, &ldquo;<B>Health Regulatory Agencies</B>&rdquo;) necessary to conduct its
business as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, including, without limitation, all
such Health Care Authorizations required by the FDA, the Australian Therapeutic Goods Administration (&ldquo;<B>TGA</B>&rdquo;), the Department
of Health and Human Services, the European Commission, the EMA or any other Health Regulatory Agencies engaged in the regulation of Biologics
(as defined in the Public Health Service Act of 1944, as amended (42 U.S.C. 6A et seq.)), except as would not be reasonably expected to
result in a Material Adverse Effect. The Company has not received any notice of proceedings, or have any knowledge of any threatened proceedings,
relating to the revocation or modification of, or non-compliance with, any such Health Care Authorization, except where such revocation,
modification or non-compliance would not result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Compliance
with Health Care Laws</U>. The Company is, and has been, in compliance with all applicable Health Care Laws, and has not engaged in activities
which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid
or any other state, federal or national health care program, except where such noncompliance, false claims liability or civil penalties
would not reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect. For purposes of this Agreement,
 &quot;<B>Health Care Laws</B>&quot; means all health care laws applicable to the Company, including, but not limited to: the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. Section&nbsp;301 et seq.), the Anti-Kickback Statute (42 U.S.C. Section&nbsp;1320a-7b(b)), the Civil
Monetary Penalties Law (42 U.S.C. &sect; 1320a-7a), the Physician Payments Sunshine Act (42 U.S.C. &sect; 1320a-7h), the Civil False Claims
Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal False Claims Law (42 U.S.C. &sect; 1320a-7b(a)), all criminal laws relating to
health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287, and the health care fraud criminal provisions
under the U.S. Health Insurance Portability and Accountability Act of 1996 (&quot;<B>HIPAA</B>&quot;) (42 U.S.C. Section&nbsp;1320d et
seq.), the exclusion laws (42 U.S.C. &sect; 1320a-7), Basic Health and Human Services Policy for Protection of Human Research Subjects
 &quot;Common Rule&quot; as codified and enforced by the Department of Health and Human Services in 45 C.F.R. part 46 and enforced by FDA
under 21 C.F.R. part 50, Laboratory Animal Welfare Act of 1966, HIPAA, as amended by the Health Information Technology for Economic and
Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.), Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX of
the Social Security Act), any and all other applicable comparable local, state, federal, national, supranational and foreign health care
laws and the regulations promulgated pursuant to such laws, each as amended from time to time. The Company has not received written notice
of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator
or governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any
Health Care Laws, and, to the knowledge of the Company, no such claim, action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action is threatened. The Company has not received any written notice of adverse filing, warning letter, untitled
letter or other correspondence or notice from the FDA, the European Commission, the EMA, the TGA or any other Health Regulatory Agencies,
or any other court or arbitrator, alleging or asserting material noncompliance with the Health Care Laws. The Company is not a party to
and has no ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements,
consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any governmental or regulatory authority.
Additionally, neither the Company, nor, to the knowledge of the Company, any of its employees, officers or directors has been excluded,
suspended or debarred from participation in any U.S. federal health care program or human research study or trial or, to the knowledge
of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected
to result in debarment, suspension or exclusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Research
Studies and Trials</U>. (A)&nbsp;The research studies and trials conducted by or, to the Company's knowledge, on behalf of, or sponsored
by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Prospectus
or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus,
as applicable, were and, if still pending, are being, conducted in all material respects in accordance with applicable experimental protocols,
procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates
comparable to those being developed by the Company and all applicable statutes, rules&nbsp;and regulations of the FDA, National Institute
of Health Department of Health and Human Services, the European Commission, the EMA, the TGA and any other Health Regulatory Agencies
to which it is subject; (B)&nbsp;the descriptions of the results of such studies and trials contained in the Registration Statement, the
Time of Sale Prospectus or the Prospectus do not contain any misstatement of a material fact or omit to state a material fact necessary
to make such statements not misleading; (C)&nbsp;the Company has no knowledge of any research studies or trials not described in the Registration
Statement, the Time of Sale Prospectus and the Prospectus the results of which reasonably call into question in any material respect the
results of the research studies and trials described in the Registration Statement, the Time of Sale Prospectus or the Prospectus; (D)&nbsp;the
Company has not received any notices or correspondence from the FDA, the European Commission, the EMA, the TGA or any Health Regulatory
Agency or any institutional review board or comparable authority requiring or threatening the premature termination, suspension, material
modification or clinical hold of any research studies or trials conducted by or on behalf of, or sponsored by, the Company or in which
the Company has participated that are described in the Registration Statement, the Time of Sale Prospectus or the Prospectus, and, to
the Company's knowledge, there are no reasonable grounds for the same; (E)&nbsp;there has not been any violation of applicable law or
regulation by the Company in any of its product development efforts, submissions or reports to the FDA, the European Commission, the EMA,
the TGA or any other Health Regulatory Agency that could reasonably be expected to require investigation, corrective action or result
in enforcement action, except where such violation would not, singly or in the aggregate, result in a Material Adverse Effect; and (F)&nbsp;the
research studies and clinical trials of Company are being conducted in an ethical and human manner under state, national or supra-national
applicable laws that are either equal or more stringent than applicable laws and regulations enforced by the Department of Health and
Human Services and FDA governing human, animal or non-human primate research participants and test subjects and such studies and the clinical
trials are conducted under the auspices of a neutral and independent Institutional Animal Care and Use Committee or Institutional Review
Board and applicable state, national, or supra national agencies responsible for oversight.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Health
Care Products Manufacturing</U>. The manufacture of the Company's products by or, to the knowledge of the Company, on behalf of the Company
is being conducted in compliance with all applicable Health Care Laws, including, without limitation, the FDA's regulation pertaining
to Biologics at 21 CFR Part&nbsp;600, and, to the extent applicable, the respective counterparts thereof promulgated by the European Commission,
the EMA, TGA or other Health Regulatory Agencies. Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the
Prospectus, the Company has not had any manufacturing site (whether owned by the Company or, to the knowledge of the Company, that of
a third party manufacturer for the Company's products) subject to an FDA, European Commission, EMA, TGA or other Health Regulatory Agency
shutdown or import or export prohibition, nor received any FDA, European Commission, EMA or other Health Regulatory Agency &quot;warning
letters,&quot; or &quot;untitled letters&quot; alleging or asserting material noncompliance with any applicable Health Care Laws, requests
to make material changes to the Company's products, processes or operations, or similar correspondence or notice from the FDA, the European
Commission, the EMA, the TGA or other Health Regulatory Agency alleging or asserting material noncompliance with any applicable Health
Care Laws, other than those that have been satisfactorily addressed and/or closed with the FDA, the European Commission, the EMA or other
Health Regulatory Agency. To the knowledge of the Company, none of the FDA, the European Commission, the EMA, the TGA or any other Health
Regulatory Agency is considering such action</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Possession
of Intellectual Property</U>. The Company owns or possesses all licenses or other rights to use all patents, trademarks, service marks,
trade names, copyrights, software and design licenses, trade secrets, manufacturing processes, other intangible property rights and know-how
as are necessary for the conduct of its business as described in the Time of Sale Prospectus, the Prospectus and the Registration Statement
(collectively, &quot;<B>Intellectual Property</B>&quot;), except where the failure to own or possess such Intellectual Property would
not reasonably be expected to have a Material Adverse Effect. The Company has not received written notice of any infringement of or conflict
with (and the Company does not know of any such infringement of or conflict with) any asserted rights of others with respect to any Intellectual
Property used by the Company that would reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(aa)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Company
IT Systems</U>. The Company owns or has a valid right to access and use all computer systems, networks, hardware, software, databases,
websites and equipment used to process, store, maintain and operate data, information and functions necessary for the conduct of its business
(the &quot;<B>Company IT Systems</B>&quot;), except where the failure to own or have the right to access the Company IT Systems would
not reasonably be expected to have a Material Adverse Effect. The Company IT Systems are adequate for, and operate and perform in all
material respects as required in connection with, the operation of the business of the Company as currently conducted except as would
not be reasonably expected, individually or in the aggregate, to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(bb)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>No
Material Defaults</U>. Neither the Company nor any of the Subsidiaries has defaulted on any installment on indebtedness for borrowed money
or on any rental on one or more long-term leases, which defaults, individually or in the aggregate, would have a Material Adverse Effect.
The Company has not filed a report pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Exchange Act since the filing of its last
Annual Report on Form&nbsp;10-K, indicating that it (i)&nbsp;has failed to pay any dividend or sinking fund installment on preferred stock
or (ii)&nbsp;has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more long-term leases, which
defaults, individually or in the aggregate, would have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(cc)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Certain
Market Activities</U>. Neither the Company nor any of its subsidiaries has taken, directly or indirectly, any action designed to or that
might cause or result in stabilization or manipulation of the price of the Shares or of any &ldquo;reference security&rdquo; (as defined
in Rule&nbsp;100 of Regulation M under the Exchange Act (&ldquo;<B>Regulation M</B>&rdquo;)) with respect to the Shares, whether to facilitate
the sale or resale of the Offered Shares or otherwise, and has taken no action which would directly or indirectly violate Regulation M.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(dd)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Broker/Dealer
Relationships</U>. Neither the Company nor any of the Subsidiaries (i)&nbsp;is required to register as a &ldquo;broker&rdquo; or &ldquo;dealer&rdquo;
in accordance with the provisions of the Exchange Act or (ii)&nbsp;directly or indirectly through one or more intermediaries, controls
or is a &ldquo;person associated with a member&rdquo; or &ldquo;associated person of a member&rdquo; (within the meaning set forth in
the FINRA Manual).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(ee)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>No
Reliance</U>. The Company has not relied upon the Underwriter or legal counsel for the Underwriter for any legal, tax or accounting advice
in connection with the offering and sale of the Offered Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(ff)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Payment
of Taxes</U>. Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect or where
such matters are the result of a pending bona fide dispute with taxing authorities, (A)&nbsp;the Company has accurately prepared and timely
filed all federal, state, foreign and other tax returns or other statements that are or were required to be filed by it, if any, and has
paid or made provision for the payment of all taxes, assessments, governmental or other similar charges, including without limitation,
all sales and use taxes and all taxes which it is obligated to withhold from amounts owing to employees, creditors and third parties,
with respect to the periods covered by such tax returns (whether or not such amounts are shown as due on any tax return), (B)&nbsp;no
deficiency assessment with respect to a proposed adjustment of the Company's federal, state, local or foreign taxes is pending or, to
the Company&rsquo;s knowledge threatened, (C)&nbsp;since the date of the most recent audited financial statements, the Company has not
incurred any liability for taxes other than in the ordinary course of its business, and (D)&nbsp;there is no tax lien, whether imposed
by any federal, state, foreign or other taxing authority, outstanding against the assets, properties or business of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(gg)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Title
to Property</U>. The Company has legal and valid title to all assets and properties described as owned by it in the Time of Sale Prospectus,
the Prospectus and the Registration Statement (whether through fee ownership, mineral estates or similar rights of ownership), in each
case free and clear of all liens, except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect, and any real property or personal property held under lease by the Company is held under a lease that is valid, existing and enforceable
by the Company with such exceptions as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect, and the Company has not received any written notice of any material claim that is adverse to the rights of the Company under any
lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(hh)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Environmental
Laws</U>. Except as set forth in the Registration Statement, the Time of Sale Prospectus or the Prospectus, (A)&nbsp;the Company is not
in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule&nbsp;of common law
or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment,
relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater,
land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened
release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products, asbestos-containing
materials or mold (collectively, &quot;<B>Hazardous Materials</B>&quot;) or to the manufacture, processing, distribution, use, treatment,
storage, disposal, transport or handling of Hazardous Materials (collectively, &quot;<B>Environmental Laws</B>&quot;), except for those
violations that would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, (B)&nbsp;the Company
has all permits, authorizations and approvals required under any applicable Environmental Laws and is in compliance in all material respects
with their requirements, (C)&nbsp;there are no pending or, to the Company&rsquo;s knowledge, threatened administrative, regulatory or
judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigations or proceedings
relating to any Environmental Law against the Company, and (D)&nbsp;to the Company's knowledge, there are no events or circumstances that
would reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private
party or governmental body or agency, against or affecting the Company relating to Hazardous Materials or any Environmental Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Disclosure
Controls</U>. The Company and each of its Subsidiaries maintain systems of internal accounting controls sufficient to provide reasonable
assurance that (i)&nbsp;transactions are executed in accordance with management&rsquo;s general or specific authorizations; (ii)&nbsp;transactions
are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and
to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&rsquo;s general or specific
authorization; and (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate
action is taken with respect to any differences. The Company&rsquo;s internal control over financial reporting is effective and the Company
is not aware of any material weaknesses in its internal control over financial reporting (other than as set forth in the Registration
Statement, Time of Sale Prospectus or Prospectus). Since the date of the latest audited financial statements of the Company included in
the Prospectus, there has been no change in the Company&rsquo;s internal control over financial reporting that has materially affected,
or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting (other than as set forth in
the Registration Statement, Time of Sale Prospectus or Prospectus). The Company has established disclosure controls and procedures (as
defined in Exchange Act Rules&nbsp;13a-15 and 15d-15) for the Company and designed such disclosure controls and procedures to ensure that
material information relating to the Company and each of its Subsidiaries is made known to the certifying officers by others within those
entities, particularly during the period in which the Company&rsquo;s Annual Report on Form&nbsp;10-K or Quarterly Report on Form&nbsp;10-Q,
as the case may be, is being prepared. The Company&rsquo;s certifying officers have evaluated the effectiveness of the Company&rsquo;s
disclosure controls and procedures as of a date within 90 days prior to the filing date of the Form&nbsp;10-K for the fiscal year most
recently ended (such date, the <B>&ldquo;Evaluation Date</B>&rdquo;). The Company presented in its Form&nbsp;10-K for the fiscal year
most recently ended the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based
on their evaluations as of the Evaluation Date and the disclosure controls and procedures are effective. Since the Evaluation Date, there
have been no significant changes in the Company&rsquo;s internal controls (as such term is defined in Item 307(b)&nbsp;of Regulation S-K
under the Securities Act) or, to the Company&rsquo;s knowledge, in other factors that could significantly affect the Company&rsquo;s internal
controls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(jj)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Sarbanes-Oxley</U>.
There is and has been no failure on the part of the Company or any of the Company&rsquo;s directors or officers, in their capacities as
such, to comply in all material respects with any applicable provisions of the Sarbanes-Oxley Act and the rules&nbsp;and regulations promulgated
thereunder. Each of the principal executive officer and the principal financial officer of the Company (or each former principal executive
officer of the Company and each former principal financial officer of the Company as applicable) has made all certifications required
by Sections 302 and 906 of the Sarbanes-Oxley Act with respect to all reports, schedules, forms, statements and other documents required
to be filed by it or furnished by it to the Commission. For purposes of the preceding sentence, &ldquo;principal executive officer&rdquo;
and &ldquo;principal financial officer&rdquo; shall have the meanings given to such terms in the Sarbanes-Oxley Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(kk)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Brokers</U>.
Neither the Company nor any of the Subsidiaries has incurred any liability for any finder&rsquo;s fees, brokerage commissions or similar
payments in connection with the transactions herein contemplated, except as may otherwise exist with respect to or pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(ll)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Employment
Laws Compliance</U>. The Company has not violated, or received any notice of any violation with respect to, any law, rule, regulation,
order, decree or judgment applicable to it and its business, including those relating to transactions with affiliates, environmental,
safety or similar laws, federal or state laws relating to discrimination in the hiring, promotion or pay of employees, federal or state
wages and hours law, the Employee Retirement Income Security Act of 1974, as amended, or the rules&nbsp;and regulations promulgated thereunder,
except for those violations that would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(mm)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Investment
Company Act</U>. Neither the Company nor any of the Subsidiaries is, or will be, either after receipt of payment for the Offered Shares
or after the application of the proceeds therefrom as described under &ldquo;Use of Proceeds&rdquo; in the Registration Statement, the
Time of Sale Prospectus or the Prospectus, required to register as an &ldquo;investment company&rdquo; or an entity &ldquo;controlled&rdquo;
by an &ldquo;investment company,&rdquo; as such terms are defined in the Investment Company Act of 1940, as amended (the &ldquo;<B>Investment
Company Act</B>&rdquo;<B>)</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(nn)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Money
Laundering Laws</U>. The Company has not, and to the Company&rsquo;s knowledge, none of the officers or directors of the Company have,
and, to the Company's knowledge, none of the Company&rsquo;s employees or agents purporting to act on behalf of the Company, as applicable,
have made any payment of funds of the Company or received or retained any funds in violation of any law, rule&nbsp;or regulation relating
to the &quot;know your customer&quot; and anti-money laundering laws of any jurisdiction (collectively, the &quot;<B>Money Laundering
Laws</B>&quot;) and no action, suit or proceeding by or before any governmental entity involving the Company with respect to the Money
Laundering Laws is pending or to the Company&rsquo;s knowledge, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(oo)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Off-Balance
Sheet Arrangements</U>. There are no transactions, arrangements and other relationships between and/or among the Company, and/or any of
its affiliates and any unconsolidated entity, including any structural finance, special purpose or limited purpose entity (each, an &ldquo;<B>Off-Balance
Sheet Transaction</B>&rdquo;) that could reasonably be expected to affect materially the Company&rsquo;s liquidity or the availability
of or requirements for its capital resources, including those Off-Balance Sheet Transactions described in the Commission&rsquo;s Statement
about Management&rsquo;s Discussion and Analysis of Financial Conditions and Results of Operations (Release Nos. 33-8056; 34-45321; FR-61),
required to be described in the Prospectus which have not been described as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(pp)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>ERISA</U>.
To the knowledge of the Company, each material employee benefit plan, within the meaning of Section&nbsp;3(3)&nbsp;of the Employee Retirement
Income Security Act of 1974 (&ldquo;<B>ERISA</B>&rdquo;), that is maintained, administered or contributed to by the Company or any of
its affiliates for employees or former employees of the Company and any of its Subsidiaries has been maintained in material compliance
with its terms and the requirements of any applicable statutes, orders, rules&nbsp;and regulations, including ERISA and the Internal Revenue
Code of 1986 (the &ldquo;<B>Code</B>&rdquo;); no prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975
of the Code, has occurred which would result in a material liability to the Company with respect to any such plan excluding transactions
effected pursuant to a statutory or administrative exemption; and for each such plan that is subject to the funding rules&nbsp;of Section&nbsp;412
of the Code or Section&nbsp;302 of ERISA, no &ldquo;accumulated funding deficiency&rdquo; as defined in Section&nbsp;412 of the Code has
been incurred, whether or not waived, and the fair market value of the assets of each such plan (excluding for these purposes accrued
but unpaid contributions) exceeds the present value of all benefits accrued under such plan determined using reasonable actuarial assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(qq)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Forward-Looking
Statements</U>. Each financial or operational projection or other &ldquo;forward-looking statement&rdquo; (as defined by Section&nbsp;27A
of the Securities Act or Section&nbsp;21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Prospectus or
the Prospectus (i)&nbsp;was so included by the Company in good faith and with reasonable basis after due consideration by the Company
of the underlying assumptions, estimates and other applicable facts and circumstances and (ii)&nbsp;is accompanied by meaningful cautionary
statements identifying those factors that could cause actual results to differ materially from those in such forward-looking statement.
No such statement was made with the knowledge of an executive officer or director of the Company that is was false or misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(rr)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Margin
Rules</U>. Neither the issuance, sale and delivery of the Offered Shares nor the application of the proceeds thereof by the Company as
described in the Registration Statement and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal
Reserve System or any other regulation of such Board of Governors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(ss)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Insurance</U>.
The Company carries, or is covered by, insurance (issued by insurers of recognized financial responsibility) in such amounts and covering
such risks as is appropriate for the conduct of its entire business and the value of its assets, all of which insurance is in full force
and effect in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(tt)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Foreign
Corrupt Practices Act</U>. Neither the Company nor any of the directors, employees or officers of the Company or, to its knowledge, any
other person acting on behalf of the Company has, directly or indirectly, given or agreed to give any money, gift or similar benefit (other
than legal price concessions to customers in the ordinary course of business) to any customer, supplier, employee or agent of a customer
or supplier, or official or employee of any governmental agency or instrumentality of any government (domestic or foreign) or any political
party or candidate for office (domestic or foreign) or other person who was, is, or may be in a position to help or hinder the business
of the Company (or assist it in connection with any actual or proposed transaction) that (i)&nbsp;might subject the Company to any damage
or penalty in any civil, criminal or governmental litigation or proceeding, (ii)&nbsp;if not given in the past, might have had a Material
Adverse Effect or (iii)&nbsp;if not continued in the future, might have a Material Adverse Effect. The Company has taken reasonable steps
to ensure that its accounting controls and procedures are sufficient to cause the Company to comply in all material respects with the
Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(uu)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>No
Conflicts</U>. Neither the execution of this Agreement, nor the issuance, offering or sale of the Offered Shares, nor the consummation
of any of the transactions contemplated herein and therein, nor the compliance by the Company with the terms and provisions hereof and
thereof will conflict with, or will result in a breach of, any of the terms and provisions of, or has constituted or will constitute a
default under, or has resulted in or will result in the creation or imposition of any lien, charge or encumbrance upon any property or
assets of the Company pursuant to the terms of any contract or other agreement to which the Company may be bound or to which any of the
property or assets of the Company is subject, except (i)&nbsp;such conflicts, breaches or defaults as may have been waived and (ii)&nbsp;such
conflicts, breaches and defaults that would not have a Material Adverse Effect; nor will such action result (x)&nbsp;in any violation
of the provisions of the organizational or governing documents of the Company, or (y)&nbsp;in any material violation of the provisions
of any statute or any order, rule&nbsp;or regulation applicable to the Company or of any Governmental Authority having jurisdiction over
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(vv)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>OFAC</U>.
The Company is not, and, to the Company&rsquo;s knowledge, none of its directors, officers agents or employees purporting to act on behalf
of the Company are currently the target of or reasonably likely to become the target of any U.S. sanctions administered by the Office
of Foreign Assets Control of the U.S. Department of the Treasury (&quot;<B>OFAC</B>&quot;); and the Company will not directly or indirectly
use the proceeds of the Offering of the Public Securities hereunder, or lend, contribute or otherwise make available such proceeds to
any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person currently the
target of any U.S. sanctions administered by OFAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(ww)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Statistical
and Market-Related Data</U>. All statistical, demographic and market-related data included in the Registration Statement, the Time of
Sale Prospectus or the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate or represent
the Company&rsquo;s good faith estimates that are made on the basis of data derived from such sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(xx)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Stock
Exchange Listing</U>. The Shares are registered pursuant to Section&nbsp;12(b)&nbsp;or 12(g)&nbsp;of the Exchange Act and are listed on
The NASDAQ Global Market (&ldquo;<B>NASDAQ</B>&rdquo;), and the Company has taken no action designed to, or likely to have the effect
of, terminating the registration of the Shares under the Exchange Act or delisting the Shares from NASDAQ, nor has the Company received
any notification that the Commission or NASDAQ is contemplating terminating such registration or listing. To the Company&rsquo;s knowledge,
it is in compliance with all applicable listing requirements of NASDAQ.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(yy)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Related-Party
Transactions</U>. There are no business relationships or related-party transactions involving the Company or any of its subsidiaries or
any other person required to be described in the Registration Statement, the Time of Sale Prospectus or the Prospectus that have not been
described as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(zz)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>FINRA
Matters</U>. All of the information provided to the Underwriters or to counsel for the Underwriters by the Company, its counsel, its officers
and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with
the offering of the Offered Shares is true, complete, correct and compliant with FINRA&rsquo;s rules&nbsp;and any letters, filings or
other supplemental information provided to FINRA pursuant to FINRA Rules&nbsp;is true, complete and correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(aaa)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Parties
to Lock-Up Agreements</U>. The Company has furnished to the Underwriters a letter agreement in the form attached hereto as <U>Exhibit&nbsp;A</U>
(the &ldquo;<B>Lock-up Agreement</B>&rdquo;) from each of the persons listed on <U>Exhibit&nbsp;B</U>. Such <U>Exhibit&nbsp;B</U> lists
under an appropriate caption the directors and executive officers of the Company. If any additional persons shall become directors or
executive officers of the Company prior to the end of the Company Lock-up Period (as defined below), the Company shall cause each such
person, prior to or contemporaneously with their appointment or election as a director or executive officer of the Company, to execute
and deliver to CF&amp;CO a Lock-up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(bbb)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Cybersecurity</U>.
The Company and its subsidiaries&rsquo; information technology assets and equipment, computers, systems, networks, hardware, software,
websites, applications, and databases (collectively, &ldquo;<B>IT Systems</B>&rdquo;) are adequate for, and operate and perform in all
material respects as required in connection with the operation of the business of the Company as currently conducted, free and clear of
known material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its subsidiaries have
implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards
to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all
IT Systems and data, including all &ldquo;Personal Data&rdquo; (defined below) and all sensitive, confidential or regulated data (&ldquo;<B>Confidential
Data</B>&rdquo;) used in connection with their businesses. &ldquo;<B>Personal Data</B>&rdquo; means (i)&nbsp;a natural person&rsquo;s
name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver&rsquo;s
license number, passport number, credit card number, bank information, or customer or account number; (ii)&nbsp;any information which
would qualify as &ldquo;personally identifying information&rdquo; under the Federal Trade Commission Act, as amended; (iii)&nbsp;&ldquo;personal
data&rdquo; as defined by the European Union General Data Protection Regulation (&ldquo;<B>GDPR</B>&rdquo;) (EU 2016/679); (iv)&nbsp;any
information which would qualify as &ldquo;protected health information&rdquo; under HIPAA; (v)&nbsp;any &ldquo;personal information&rdquo;
as defined by the California Consumer Privacy Act (&ldquo;<B>CCPA</B>&rdquo;); and (vi)&nbsp;any other piece of information that allows
the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified
person&rsquo;s health or sexual orientation. There have been no breaches, violations, outages or unauthorized uses of or accesses to same,
except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents
under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material compliance with
all applicable laws or statutes and all judgments, orders, rules&nbsp;and regulations of any court or arbitrator or governmental or regulatory
authority, internal policies and contractual obligations relating to the privacy and security of IT Systems, Confidential Data, and Personal
Data and to the protection of such IT Systems, Confidential Data, and Personal Data from unauthorized use, access, misappropriation or
modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(ccc)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><U>Compliance
with Data Privacy Laws</U>. The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable
state and federal data privacy and security laws and regulations, including without limitation HIPAA, CCPA, and GDPR (collectively, the
 &ldquo;<B>Privacy Laws</B>&rdquo;). To ensure compliance with the Privacy Laws, the Company has in place, complies with, and takes appropriate
steps to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection,
storage, use, processing, disclosure, handling, and analysis of Personal Data and Confidential Data (the &ldquo;<B>Policies</B>&rdquo;).
The Company has at all times made all disclosures to users or customers required by applicable laws and regulatory rules&nbsp;or requirements,
and none of such disclosures made or contained in any Policy have been inaccurate or in violation of any applicable laws and regulatory
rules&nbsp;or requirements in any material respect. The Company further certifies that neither it nor any subsidiary: (i)&nbsp;has received
notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has
no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;is currently conducting
or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is
a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any certificate signed by
any officer of the Company or any of its subsidiaries and delivered to any Underwriter or to counsel for the Underwriters in connection
with the offering, or the purchase and sale, of the Offered Shares shall be deemed a representation and warranty by the Company to each
Underwriter as to the matters covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has a reasonable
basis for making each of the representations set forth in this Section&nbsp;1. The Company acknowledges that the Underwriters and, for
purposes of the opinions to be delivered pursuant to Section&nbsp;6, counsel to the Company and counsel to the Underwriters, will rely
upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Purchase,
Sale and Delivery of the Offered Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>The
Firm Shares</U>. Upon the terms herein set forth, the Company agrees to issue and sell to the several Underwriters an aggregate of 5,000,000
Firm Shares. On the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions
herein set forth, the Underwriters agree, severally and not jointly, to purchase from the Company the respective number of Firm Shares
set forth opposite their names on <U>Schedule A</U>. The purchase price per Firm Share to be paid by the several Underwriters to the Company
shall be $1.128 per share, or with respect to (a)&nbsp;certain investors and as set forth on <U>Schedule A-1</U>, an average purchase
price for all shares purchased by such investor of $1.176 per share and (b)&nbsp;a certain director and as set forth on <U>Schedule A-2</U>,
a purchase price of $1.200 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>The
First Closing Date</U>. Delivery of certificates for the Firm Shares to be purchased by the Underwriters and payment therefor shall be
made at the offices of McGuireWoods LLP, 1251 6<SUP>th</SUP> Avenue, 20<SUP>th</SUP> Floor, New York 10021 (or such other place as may
be agreed to by the Company and the Representative) at 9:00 a.m.&nbsp;Eastern time, on November&nbsp;15, 2022 or such other time and date
not later than 5:30 p.m.&nbsp;Eastern time, on November&nbsp;15, 2022 as the Representative shall designate by notice to the Company (the
time and date of such closing are called the &ldquo;<B>First Closing Date</B>&rdquo;). The Company hereby acknowledges that circumstances
under which the Representative may provide notice to postpone the First Closing Date as originally scheduled include, but are not limited
to, any determination by the Company or the Representative to recirculate to the public copies of an amended or supplemented Prospectus
or a delay as contemplated by the provisions of Section&nbsp;11.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>The
Option Shares; Option Closing Date</U>. In addition, on the basis of the representations, warranties and agreements herein contained,
and upon the terms but subject to the conditions herein set forth, the Company hereby grants an option to the several Underwriters to
purchase, severally and not jointly, up to an aggregate of 750,000 Option Shares from the Company at the purchase price per share to be
paid by the Underwriters for the Firm Shares. The option granted hereunder may be exercised at any time and from time to time in whole
or in part upon notice by the Representative to the Company, which notice may be given at any time within 30 days from the date of this
Agreement. Such notice shall set forth (i)&nbsp;the aggregate number of Option Shares as to which the Underwriters are exercising the
option and (ii)&nbsp;the time, date and place at which certificates for the Option Shares will be delivered (which time and date may be
simultaneous with, but not earlier than, the First Closing Date; and in the event that such time and date are simultaneous with the First
Closing Date, the term &ldquo;<B>First Closing Date</B>&rdquo; shall refer to the time and date of delivery of certificates for the Firm
Shares and such Option Shares). Any such time and date of delivery, if subsequent to the First Closing Date, is called an &ldquo;<B>Option
Closing Date,</B>&rdquo; shall be determined by the Representative and shall not be earlier than three or later than five full Business
Days after delivery of such notice of exercise. If any Option Shares are to be purchased, (a)&nbsp;each Underwriter agrees, severally
and not jointly, to purchase the number of Option Shares (subject to such adjustments to eliminate fractional shares as the Representative
may determine) that bears the same proportion to the total number of Option Shares to be purchased as the number of Firm Shares set forth
on <U>Schedule A</U> opposite the name of such Underwriter bears to the total number of Firm Shares and (b)&nbsp;the Company agrees to
sell the number of Option Shares set forth in the paragraph &ldquo;Introductory&rdquo; of this Agreement (subject to such adjustments
to eliminate fractional shares as the Representative may determine). The Representative may cancel the option at any time prior to its
expiration by giving written notice of such cancellation to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Public
Offering of the Offered Shares</U>. The Representative hereby advises the Company that the Underwriters intend to offer for sale to the
public, initially on the terms set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, their respective
portions of the Offered Shares as soon after this Agreement has been executed as the Representative, in its sole judgment, has determined
is advisable and practicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Payment
for the Offered Shares</U>. (i)&nbsp;Payment for the Offered Shares shall be made at the First Closing Date (and, if applicable, at each
Option Closing Date) by wire transfer of immediately available funds to the order of the Company. (ii)&nbsp;It is understood that the
Representative has been authorized, for their own account and the accounts of the several Underwriters, to accept delivery of and receipt
for, and make payment of the purchase price for, the Firm Shares and any Option Shares the Underwriters have agreed to purchase. CF&amp;Co.,
individually and not as the Representative of the Underwriters, may (but shall not be obligated to) make payment for any Offered Shares
to be purchased by any Underwriter whose funds shall not have been received by the Representative by the First Closing Date or the applicable
Option Closing Date, as the case may be, for the account of such Underwriter, but any such payment shall not relieve such Underwriter
from any of its obligations under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Delivery
of the Offered Shares</U>. The Company shall deliver, or cause to be delivered to the Representative for the accounts of the several Underwriters
certificates for the Firm Shares at the First Closing Date, against the irrevocable release of a wire transfer of immediately available
funds for the amount of the purchase price therefor. The Company shall also deliver, or cause to be delivered through the facilities of
DTC unless the Representative shall otherwise instruct, to the Representative for the accounts of the several Underwriters, certificates
for the Option Shares the Underwriters have agreed to purchase at the First Closing Date or the applicable Option Closing Date, as the
case may be, against the release of a wire transfer of immediately available funds for the amount of the purchase price therefor. If the
Representative so elects, delivery of the Offered Shares may be made by credit to the accounts designated by the Representative through
The Depository Trust Company&rsquo;s full fast transfer or DWAC programs. The certificates for the Offered Shares shall be registered
in such names and denominations as the Representative shall have requested at least two full Business Days prior to the First Closing
Date (or the applicable Option Closing Date, as the case may be) and shall be made available for inspection on the Business Day preceding
the First Closing Date (or the applicable Option Closing Date, as the case may be) at a location in New York City as the Representative
may designate. Time shall be of the essence, and delivery at the time and place specified in this Agreement is a further condition to
the obligations of the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Additional
Covenants of the Company</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company further covenants
and agrees with each Underwriter as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Delivery
of Registration Statement, Time of Sale Prospectus and Prospectus</U>. The Company shall furnish to the Representative in New York City,
without charge, prior to 10:00 a.m.&nbsp;New York City time on the Business Day next succeeding the date of this Agreement and during
the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through
compliance with Rule&nbsp;172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares, as many copies
of the Time of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the Registration Statement as the Representative
may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Representative&rsquo;s
Review of Proposed Amendments and Supplements</U>. During the period when a prospectus relating to the Offered Shares is required by the
Securities Act to be delivered (whether physically or through compliance with Rule&nbsp;172 under the Securities Act or any similar rule),
the Company (i)&nbsp;will furnish to the Representative for review, a reasonable period of time prior to the proposed time of filing of
any proposed amendment or supplement to the Registration Statement, a copy of each such amendment or supplement and (ii)&nbsp;will not
amend or supplement the Registration Statement (including any amendment or supplement through incorporation of any report filed under
the Exchange Act) without the Representative&rsquo;s prior written consent. Prior to amending or supplementing any preliminary prospectus,
the Time of Sale Prospectus or the Prospectus (including any amendment or supplement through incorporation of any report filed under the
Exchange Act), the Company shall furnish to the Representative for review, a reasonable amount of time prior to the time of filing or
use of the proposed amendment or supplement, a copy of each such proposed amendment or supplement. The Company shall not file or use any
such proposed amendment or supplement without the Representative&rsquo;s prior written consent, which consent shall not be unreasonably
withheld, conditioned or delayed. The Company shall file with the Commission within the applicable period specified in Rule&nbsp;424(b)&nbsp;under
the Securities Act any prospectus required to be filed pursuant to such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Free
Writing Prospectuses</U>. The Company shall furnish to the Representative for review, a reasonable amount of time prior to the proposed
time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto prepared by or on
behalf of, used by, or referred to by the Company, and the Company shall not file, use or refer to any proposed free writing prospectus
or any amendment or supplement thereto without the Representative&rsquo;s prior written consent, which consent shall not be unreasonably
withheld, conditioned or delayed. The Company shall furnish to each Underwriter, without charge, as many copies of any free writing prospectus
prepared by or on behalf of, used by or referred to by the Company as such Underwriter may reasonably request. If at any time when a prospectus
is required by the Securities Act to be delivered (whether physically or through compliance with Rule&nbsp;172 under the Securities Act
or any similar rule) in connection with sales of the Offered Shares (but in any event if at any time through and including the First Closing
Date) there occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used
by, or referred to by the Company conflicted or would conflict with the information contained in the Registration Statement or included
or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances prevailing at such time, not misleading, the Company shall promptly amend or supplement
such free writing prospectus to eliminate or correct such conflict so that the statements in such free writing prospectus as so amended
or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances prevailing at such time, not misleading, as the case may be; <U>provided</U>, <U>however</U>,
that prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the Representative for review,
a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free
writing prospectus, and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the
Representative&rsquo;s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Filing
of Underwriter Free Writing Prospectuses</U>. The Company shall not take any action that would result in an Underwriter or the Company
being required to file with the Commission pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act a free writing prospectus prepared
by or on behalf of such Underwriter that such Underwriter otherwise would not have been required to file thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Amendments
and Supplements to Time of Sale Prospectus</U>. If the Time of Sale Prospectus is being used to solicit offers to buy the Offered Shares
at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition exist as a result
of which it is necessary to amend or supplement the Time of Sale Prospectus so that the Time of Sale Prospectus does not include an untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition exist as a result of which the Time
of Sale Prospectus conflicts with the information contained in the Registration Statement, or if, in the opinion of counsel for the Underwriters,
it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable Law, the Company shall (subject to Section&nbsp;3(b)&nbsp;and
Section&nbsp;3(c)) promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon
request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended
or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances when delivered to a prospective purchaser, not misleading or so that the Time of
Sale Prospectus, as amended or supplemented, will no longer conflict with the information contained in the Registration Statement, or
so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Notifications and Required Actions</U>. After the date of this Agreement, the Company shall promptly advise the Representative in writing
of: (i)&nbsp;the receipt of any comments of, or requests for additional or supplemental information from, the Commission relating to the
Registration Statement; (ii)&nbsp;the time and date of any filing of any post-effective amendment to the Registration Statement or any
amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus; (iii)&nbsp;the
time and date that any post-effective amendment to the Registration Statement becomes effective; and (iv)&nbsp;the issuance by the Commission
of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or any amendment
or supplement to any preliminary prospectus, the Time of Sale Prospectus or the Prospectus or of any order preventing or suspending the
use of any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus, or of any proceedings to
remove, suspend or terminate from listing or quotation the Shares from any securities exchange upon which they are listed for trading
or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes. If the Commission
shall enter any such stop order at any time, the Company will use its best efforts to obtain the lifting of such order as soon as reasonably
practicable. Additionally, the Company agrees that it shall comply with all applicable provisions of Rule&nbsp;424(b), Rule&nbsp;433 and
Rule&nbsp;430A under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule&nbsp;424(b)&nbsp;or
Rule&nbsp;433 were received in a timely manner by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Amendments
and Supplements to the Prospectus and Other Securities Act Matters</U>. If any event shall occur or condition exist as a result of which
it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or
omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus
is delivered (whether physically or through compliance with Rule&nbsp;172 under the Securities Act or any similar rule) to a purchaser,
not misleading, or if in the opinion of the Representative or counsel for the Underwriters it is otherwise necessary to amend or supplement
the Prospectus to comply with applicable Law, the Company agrees (subject to Section&nbsp;3(b)&nbsp;and Section&nbsp;3(c)) to promptly
prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments or supplements
to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus
is delivered (whether physically or through compliance with Rule&nbsp;172 under the Securities Act or any similar rule) to a purchaser,
not misleading or so that the Prospectus, as amended or supplemented, will comply with applicable Law. Neither the Representative&rsquo;s
consent to, nor delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&rsquo;s obligations under
Section&nbsp;3(b)&nbsp;or Section&nbsp;3(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Blue
Sky Compliance</U>. The Company shall cooperate with the Representative and counsel for the Underwriters to qualify or register the Offered
Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky Laws or Canadian provincial securities
Laws (or other foreign Laws) of those jurisdictions designated by the Representative, shall comply with such Laws and shall continue such
qualifications, registrations and exemptions in effect so long as required for the distribution of the Offered Shares. The Company shall
not be required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such
jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation. The Company will advise
the Representative promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Offered
Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the
event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best efforts to
obtain the withdrawal thereof as soon as reasonably practicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Use
of Proceeds</U>. The Company shall apply the net proceeds from the sale of the Offered Shares sold by it in the manner described under
the caption &ldquo;Use of Proceeds&rdquo; in the Registration Statement, the Time of Sale Prospectus and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transfer
Agent</U>. The Company shall maintain, at its expense, a registrar and transfer agent for the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Earnings
Statement</U>. The Company will make generally available to its security holders and to the Representative as soon as practicable an earnings
statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company
commencing after the date of this Agreement that will satisfy the provisions of Section&nbsp;11(a)&nbsp;of the Securities Act and the
rules&nbsp;and regulations of the Commission thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Continued
Compliance with Securities Laws</U>. The Company will comply with the Securities Act and the Exchange Act so as to permit the completion
of the distribution of the Offered Shares as contemplated by this Agreement<B>, </B>the Registration Statement, the Time of Sale Prospectus
and the Prospectus. Without limiting the generality of the foregoing, the Company will, during the period when a prospectus relating to
the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule&nbsp;172 under
the Securities Act or any similar rule), file on a timely basis with the Commission and NASDAQ all reports and documents required to be
filed under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Listing</U>.
The Company will use its best efforts to list, subject to notice of issuance, the Shares on NASDAQ.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Company
to Provide Copy of the Prospectus in Form&nbsp;That May&nbsp;be Downloaded from the Internet</U>. If requested by the Representative,
the Company shall cause to be prepared and delivered, at its expense, within one Business Day from the effective date of this Agreement,
to CF&amp;CO, an &ldquo;<B>electronic Prospectus</B>&rdquo; to be used in connection with the offering and sale of the Offered Shares.
As used herein, the term &ldquo;<B>electronic Prospectus</B>&rdquo; means a form of Time of Sale Prospectus, and any amendment or supplement
thereto, that meets each of the following conditions: (i)&nbsp;it shall be encoded in an electronic format, satisfactory to CF&amp;CO,
that may be transmitted electronically by CF&amp;CO to offerees and purchasers of the Offered Shares; (ii)&nbsp;it shall disclose the
same information as the paper Time of Sale Prospectus, except to the extent that graphic and image material cannot be disseminated electronically,
in which case such graphic and image material shall be replaced in the electronic Prospectus with a fair and accurate narrative description
or tabular representation of such material, as appropriate; and (iii)&nbsp;it shall be in or convertible into a paper format or an electronic
format, satisfactory to CF&amp;CO, that will allow investors to store and have continuously ready access to the Time of Sale Prospectus
at any future time, without charge to investors (other than any fee charged for subscription to the Internet as a whole and for on-line
time). The Company hereby confirms that it has included or will include in the Prospectus filed pursuant to EDGAR or otherwise with the
Commission and in the Registration Statement at the time it was declared effective an undertaking that, upon receipt of a request by an
investor or his or her representative, the Company shall transmit or cause to be transmitted promptly, without charge, a paper copy of
the Time of Sale Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Agreement
Not to Offer or Sell Additional Shares</U>. During the period commencing on and including the date hereof and continuing through and including
the 90th day following the date of the Prospectus (such period, as extended as described below, being referred to herein as the &ldquo;<B>Lock-up
Period</B>&rdquo;), the Company will not, without the prior written consent of CF&amp;CO (which consent may be withheld in its sole discretion),
directly or indirectly: (i)&nbsp;sell, offer to sell, contract to sell or lend any Shares or Related Securities (as defined below); (ii)&nbsp;effect
any short sale, or establish or increase any &ldquo;put equivalent position&rdquo; (as defined in Rule&nbsp;16a-1(h)&nbsp;under the Exchange
Act) or liquidate or decrease any &ldquo;call equivalent position &ldquo; (as defined in Rule&nbsp;16a-1(b)&nbsp;under the Exchange Act)
of any Shares or Related Securities; (iii)&nbsp;pledge, hypothecate or grant any security interest in; (iv)&nbsp;in any other way transfer
or dispose of any Shares or Related Securities; (v)&nbsp;enter into any swap, hedge or similar arrangement or agreement that transfers,
in whole or in part, the economic risk of ownership of any Shares or Related Securities, regardless of whether any such transaction is
to be settled in securities, in cash or otherwise; (vi)&nbsp;announce the offering of any Shares or Related Securities; (vii)&nbsp;file
any registration statement under the Securities Act in respect of any Shares or Related Securities (other than as contemplated by this
Agreement with respect to the Offered Shares); or (viii)&nbsp;publicly announce the intention to do any of the foregoing; <U>provided</U>,
<U>however</U>, that the Company may (A)&nbsp;effect the transactions contemplated hereby and (B)&nbsp;issue Shares or options to purchase
Shares, or issue Shares upon exercise of options, pursuant to any equity incentive, employee stock purchase, stock option, stock bonus
or other stock plan or arrangement described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, but only if
the holders of such Shares or options agree in writing with the Underwriters not to sell, offer, dispose of or otherwise transfer any
such Shares or options during such Lock-up Period without the prior written consent of CF&amp;CO (which consent may be withheld in its
sole discretion). For purposes of the foregoing, &ldquo;<B>Related Securities</B>&rdquo; shall mean any options or warrants or other rights
to acquire Shares or any securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights
ultimately exchangeable or exercisable for, or convertible into, Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Future
Reports to the Representative</U>. During the period of five years hereafter, the Company will furnish to the Representative, c/o Cantor
Fitzgerald&nbsp;&amp; Co., at 499 Park Avenue, New York, New York 10022, Attention: Equity Capital Markets, with copies to Cantor Fitzgerald&nbsp;&amp;
Co., 499 Park Avenue, New York, New York 10022, Attention: General Counsel: (i)&nbsp;as soon as practicable after the end of each fiscal
year, copies of the Annual Report of the Company containing the balance sheet of the Company as of the close of such fiscal year and statements
of income, stockholders&rsquo; equity and cash flows for the year then ended and the opinion thereon of the Company&rsquo;s independent
public or certified public accountants; (ii)&nbsp;as soon as practicable after the filing thereof, copies of each proxy statement, Annual
Report on Form&nbsp;10-K, Quarterly Report on Form&nbsp;10-Q, Current Report on Form&nbsp;8-K or other report filed by the Company with
the Commission, FINRA or any securities exchange; and (iii)&nbsp;as soon as available, copies of any report or communication of the Company
furnished or made available generally to holders of its capital stock; <U>provided</U>, <U>however</U>, that the requirements of this
Section&nbsp;3(p)&nbsp;shall be satisfied to the extent that such reports, statement, communications, financial statements or other documents
are available on EDGAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Investment
Limitation</U>. The Company shall not invest or otherwise use the proceeds received by the Company from its sale of the Offered Shares
in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Stabilization or Manipulation; Compliance with Regulation M</U>. The Company will not take, and will ensure that no affiliate of the Company
will take, directly or indirectly, without giving effect to activities by the Underwriters, any action designed to or that might cause
or result in stabilization or manipulation of the price of the Shares or any reference security with respect to the Shares, whether to
facilitate the sale or resale of the Offered Shares or otherwise, and the Company will, and shall cause each of its affiliates to, comply
with all applicable provisions of Regulation M.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Enforce
Lock-Up Agreements</U>. During the Lock-up Period, the Company will enforce all agreements between the Company and any of its security
holders that restrict or prohibit, expressly or in operation, the offer, sale or transfer of Shares or Related Securities or any of the
other actions restricted or prohibited under the terms of the form of Lock-up Agreement. In addition, the Company will direct the transfer
agent to place stop transfer restrictions upon any such securities of the Company that are bound by such &ldquo;lock-up&rdquo; agreements
for the duration of the periods contemplated in such agreements, including &ldquo;lock-up&rdquo; agreements entered into by the Company&rsquo;s
officers and directors and stockholders pursuant to Section&nbsp;6(j)&nbsp;hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Company
to Provide Interim Financial Statements</U>. Prior to the First Closing Date and each applicable Option Closing Date, the Company will
furnish the Underwriters, as soon as they have been prepared by or are available to the Company, a copy of any unaudited interim financial
statements of the Company for any period subsequent to the period covered by the most recent financial statements appearing in the Registration
Statement and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Amendments
and Supplements to Permitted Section&nbsp;5(d)Communications</U>. If at any time following the distribution of any Permitted Section&nbsp;5(d)&nbsp;Communication,
there occurred or occurs an event or development as a result of which such Permitted Section&nbsp;5(d)&nbsp;Communication included or
would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify
the Representative and will promptly amend or supplement, at its own expense, such Permitted Section&nbsp;5(d)&nbsp;Communication to eliminate
or correct such untrue statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Representative, on behalf
of the several Underwriters, may, in its sole discretion, waive in writing the performance by the Company of any one or more of the foregoing
covenants or extend the time for their performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Payment
of Expenses</U>. The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations
hereunder and in connection with the transactions contemplated hereby, including (i)&nbsp;all expenses incident to the issuance and delivery
of the Offered Shares (including all printing and engraving costs), (ii)&nbsp;all fees and expenses of the registrar and transfer agent
of the Shares, (iii)&nbsp;all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Offered
Shares to the Underwriters, (iv)&nbsp;all fees and expenses of the Company&rsquo;s counsel, independent public or certified public accountants
and other advisors, (v)&nbsp;all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution
of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Time of
Sale Prospectus, the Prospectus, each free writing prospectus prepared by or on behalf of, used by, or referred to by the Company, and
each preliminary prospectus, each Permitted Section&nbsp;5(d)&nbsp;Communication, and all amendments and supplements thereto, and this
Agreement, (vi)&nbsp;all filing fees, reasonable and documented attorneys&rsquo; fees and expenses incurred by the Company or the Underwriters
in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the
Offered Shares for offer and sale under the state securities or blue sky Laws or the provincial securities Laws of Canada, and, if requested
by the Representative, preparing and printing a &ldquo;Blue Sky Survey&rdquo; or memorandum and a &ldquo;Canadian wrapper&rdquo;, and
any supplements thereto, advising the Underwriters of such qualifications, registrations and exemptions, in an amount not to exceed $7,500,
(vii)&nbsp;the fees and expenses of the Underwriters including the fees and expenses of the counsel to the Underwriters, payable upon
the execution of this Agreement, in an amount not to exceed $100,000, (viii)&nbsp;the costs and expenses of the Company relating to investor
presentations on any &ldquo;road show&rdquo;, any Permitted Section&nbsp;5(d)&nbsp;Communication or any Section&nbsp;5(d)&nbsp;Oral Communication
undertaken in connection with the offering of the Shares, including expenses associated with the preparation or dissemination of any electronic
road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection
with the road show presentations with the prior approval of the Company, travel and lodging expenses of the Representative, employees
and officers of the Company and any such consultants, (ix)&nbsp;the fees and expenses associated with listing the Shares on NASDAQ, and
(x)&nbsp;all other fees, costs and expenses of the nature referred to in Item 13 of Part&nbsp;II of the Registration Statement. Any such
amount payable to the Underwriters may be deducted from the purchase price for the Offered Shares. Except as provided in this Section&nbsp;4
or in Section&nbsp;7, Section&nbsp;9 or Section&nbsp;10, the Underwriters shall pay their own expenses, including the fees and disbursements
of their counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Covenant
of the Underwriters</U>. Each Underwriter severally and not jointly covenants with the Company not to take any action that would result
in the Company being required to file with the Commission pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act a free writing prospectus
prepared by or on behalf of such Underwriter that otherwise would not, but for such actions, be required to be filed by the Company under
Rule&nbsp;433(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Conditions
of the Obligations of the Underwriters</U>. The respective obligations of the several Underwriters hereunder to purchase and pay for the
Offered Shares as provided herein on the First Closing Date and, with respect to the Option Shares, each Option Closing Date, shall be
subject to the accuracy of the representations and warranties on the part of the Company set forth in Section&nbsp;1 as of the date hereof
and as of the First Closing Date as though then made and, with respect to the Option Shares, as of each Option Closing Date as though
then made, to the timely performance by the Company of its covenants and other obligations hereunder, and to each of the following additional
conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Comfort
Letter</U>. On the date hereof, the Representative shall have received from Ernst&nbsp;&amp; Young LLP, independent registered public
accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance satisfactory to the Representative,
containing statements and information of the type ordinarily included in accountant&rsquo;s &ldquo;comfort letters&rdquo; to underwriters,
delivered according to Statement of Auditing Standards No.&nbsp;72 (or any successor bulletin), with respect to the audited and unaudited
financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus, and each
free writing prospectus, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Compliance
with Registration Requirements; No Stop Order; No Objection from FINRA</U>. For a period from and after the date of this Agreement and
through and including the First Closing Date and, with respect to any Option Shares purchased after the First Closing Date, each Option
Closing Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company shall have filed the Prospectus with the Commission (including the information required by Rule&nbsp;430A under the Securities
Act) in the manner and within the time period required by Rule&nbsp;424(b)&nbsp;under the Securities Act; or the Company shall have filed
a post-effective amendment to the Registration Statement containing the information required by such Rule&nbsp;430A, and such post-effective
amendment shall have become effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">No
stop order suspending the effectiveness of the Registration Statement or any post-effective amendment to the Registration Statement shall
be in effect, and no proceedings for such purpose shall have been instituted or threatened by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">FINRA
shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Material Adverse Effect or Ratings Agency Change</U>. For the period from and after the date of this Agreement and through and including
the First Closing Date and, with respect to any Option Shares purchased after the First Closing Date, each Option Closing Date, (a)&nbsp;in
the judgment of the Representative there shall not have occurred any Material Adverse Effect, and (b)&nbsp;there shall not have occurred
a downgrading in or withdrawal of the rating assigned to any of the Company&rsquo;s securities (other than asset-backed securities) by
any rating organization or a public announcement by any rating organization that it has under surveillance or review its rating of any
of the Company&rsquo;s securities (other than asset-backed securities), the effect of which, in the case of any such action by a rating
organization described above, would cause a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Opinion
of Counsel for the Company</U>. On each of the First Closing Date and each Option Closing Date the Representative shall have received
the opinion and negative assurance letter of Troutman Pepper Hamilton Sanders LLP, counsel for the Company, dated as of such date, in
form and substance reasonably satisfactory to the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Opinion
of Intellectual Property Counsel</U>. On each of the First Closing Date and each Option Closing Date, the Representative shall have received
the opinion of DLA Piper LLP (US), counsel for the Company with respect to intellectual property matters, dated as of such date, in form
and substance reasonably satisfactory to the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Opinion
of Counsel for the Underwriters</U>. On each of the First Closing Date and each Option Closing Date the Representative shall have received
the opinion of McGuireWoods LLP, counsel for the Underwriters in connection with the offer and sale of the Offered Shares, in form and
substance satisfactory to the Representative, dated as of such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Officers&rsquo;
Certificate</U>. On each of the First Closing Date and each Option Closing Date, the Representative shall have received a certificate
executed by the Chief Executive Officer or President of the Company and the Chief Financial Officer of the Company, dated as of such date,
to the effect set forth in Section&nbsp;6(b)(ii)&nbsp;and further to the effect that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">for
the period from and including the date of this Agreement through and including such date, there has not occurred any Material Adverse
Effect;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
representations, warranties and covenants of the Company set forth in Section&nbsp;1 are true and correct with the same force and effect
as though expressly made on and as of such date; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Company has complied with all the agreements hereunder and satisfied all the conditions on its part to be performed or satisfied hereunder
at or prior to such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Chief
Financial Officer&rsquo;s Certificate</U>. On each of the First Closing Date and each Option Closing Date, the Representative shall have
received a certificate executed by the Chief Financial Officer of the Company, dated as of such date, in the form attached as <U>Exhibit&nbsp;C</U>
hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Bring-down
Comfort Letter</U>. On each of the First Closing Date and each Option Closing Date the Representative shall have received from Ernst&nbsp;&amp;
Young LLP, independent registered public accountants for the Company, a letter dated such date, in form and substance satisfactory to
the Representative, which letter shall: (i)&nbsp;reaffirm the statements made in the letter furnished by them pursuant to Section&nbsp;6(a),
except that the specified date referred to therein for the carrying out of procedures shall be no more than three Business Days prior
to the First Closing Date or the applicable Option Closing Date, as the case may be; and (ii)&nbsp;cover certain financial information
contained in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Lock-Up
Agreements</U>. On or prior to the date hereof, the Company shall have furnished to the Representative an agreement in the form of <U>Exhibit&nbsp;A</U>
hereto from the directors and officers (as defined in Rule&nbsp;16a-1(f)&nbsp;under the Exchange Act), and each such agreement shall be
in full force and effect on each of the First Closing Date and each Option Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Rule&nbsp;462(b)&nbsp;Registration
Statement</U>. In the event that a Rule&nbsp;462(b)&nbsp;Registration Statement is filed in connection with the offering contemplated
by this Agreement, such Rule&nbsp;462(b)&nbsp;Registration Statement shall have been filed with the Commission on the date of this Agreement
and shall have become effective automatically upon such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>NASDAQ</U>.
The Company shall have submitted a listing of additional shares notification form to NASDAQ with respect to the Offered Shares and shall
have received no objection thereto from NASDAQ.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Additional
Documents</U>. On or before each of the First Closing Date and each Option Closing Date, the Representative and counsel for the Underwriters
shall have received such information, documents and opinions as they may reasonably request for the purposes of enabling them to pass
upon the issuance and sale of the Offered Shares as contemplated herein, or in order to evidence the accuracy of any of the representations
and warranties, or the satisfaction of any of the conditions or agreements, herein contained; and all proceedings taken by the Company
in connection with the issuance and sale of the Offered Shares as contemplated herein and in connection with the other transactions contemplated
by this Agreement shall be satisfactory in form and substance to the Representative and counsel for the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any condition specified
in this Section&nbsp;6 is not satisfied when and as required to be satisfied, this Agreement may be terminated by the Representative by
notice from the Representative to the Company at any time on or prior to the First Closing Date and, with respect to the Option Shares,
at any time on or prior to the applicable Option Closing Date, which termination shall be without liability on the part of any party to
any other party, except that Section&nbsp;4, Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall
survive such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Reimbursement
of Underwriters&rsquo; Expenses</U>. If this Agreement is terminated by the Representative pursuant to Section&nbsp;6, Section&nbsp;11
or Section&nbsp;12, or if the sale to the Underwriters of the Offered Shares on the First Closing Date is not consummated because of any
refusal, inability or failure on the part of the Company to perform any agreement herein or to comply with any provision hereof, the Company
agrees to reimburse the Representative and the other Underwriters (or such Underwriters as have terminated this Agreement with respect
to themselves), severally, upon demand for all out-of-pocket expenses that shall have been reasonably incurred by the Representative and
the Underwriters in connection with the proposed purchase and the offering and sale of the Offered Shares, including reasonable and documented
fees and disbursements of counsel up to $66,000, printing expenses, travel expenses, postage, facsimile and telephone charges.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Effectiveness
of this Agreement</U>. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnification</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnification
of the Underwriters</U>. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates and their respective partners,
members, directors, officers, employees and agents, and each person, if any, who controls each Underwriter or any affiliate within the
meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, arising out of or based upon any untrue
statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), or the omission
or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading,
or arising out of any untrue statement or alleged untrue statement of a material fact included in any preliminary prospectus, Time of
Sale Prospectus, any free writing prospectus, any Marketing Material, any Section&nbsp;5(d)&nbsp;Written Communication or the Prospectus
(or any amendment or supplement to the foregoing), or the omission or alleged omission therefrom of a material fact necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, to the extent of the aggregate amount
paid in settlement of any litigation, or any investigation or proceeding by any Governmental Authority, commenced or threatened, or of
any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; <U>provided</U>
that (subject to Section&nbsp;9(d)) any such settlement is effected with the written consent of the Company, which consent shall not unreasonably
be delayed, conditioned or withheld; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">against
any and all expense whatsoever, as incurred (including the fees and disbursements of counsel), reasonably incurred in investigating, preparing
or defending against any litigation, or any investigation or proceeding by any Governmental Authority, commenced or threatened, or any
claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission (whether or not a
party), to the extent that any such expense is not paid under (i)&nbsp;or (ii)&nbsp;above;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>provided</U></FONT>,
<U>however</U>, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out
of any untrue statement or omission or alleged untrue statement or omission made solely in reliance upon and in conformity with the Underwriter
Information (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: a2 -->
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnification
of the Company, its Directors and Officers</U>. Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the
Company, and its directors, each officer of the Company who signed the Registration Statement and each person, if any, who controls the
Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, against any and all loss,
liability, claim, damage and expense described in the indemnity contained in Section&nbsp;9(a), as incurred, but only with respect to
untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement, any preliminary prospectus,
the Time of Sale Prospectus, any free writing prospectus, any Section&nbsp;5(d)&nbsp;Written Communication or the Prospectus (or any
amendment or supplement to the foregoing), in reliance upon and in conformity with information relating to such Underwriter and furnished
to the Company in writing by such Underwriter or Underwriters expressly for use therein. The Company hereby acknowledges that the only
information that the Underwriter or Underwriters has furnished to the Company expressly for use in the Registration Statement, any preliminary
prospectus, the Time of Sale Prospectus, any free writing prospectus, any Section&nbsp;5(d)&nbsp;Written Communication or the Prospectus
(or any amendment or supplement to the foregoing) are the statements set forth in the third sentence of the third paragraph, the fifth
paragraph and the first sentence of the thirteenth paragraph under the caption &ldquo;Underwriting&rdquo; in the Preliminary Prospectus
and Prospectus (the &ldquo;<B>Underwriter Information</B>&rdquo;).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notifications
and Other Indemnification Procedures</U>. Any party that proposes to assert the right to be indemnified under this Section&nbsp;9 will,
promptly after receipt of notice of commencement of any action against such party in respect of which a claim is to be made against an
indemnifying party or parties under this Section&nbsp;9, notify each such indemnifying party of the commencement of such action, enclosing
a copy of all papers served, but the omission so to notify such indemnifying party will not relieve the indemnifying party from (i)&nbsp;any
liability that it might have to any indemnified party otherwise than under this Section&nbsp;9 and (ii)&nbsp;any liability that it may
have to any indemnified party under the foregoing provision of this Section&nbsp;9 unless, and only to the extent that, such omission
results in the forfeiture of substantive rights or defenses by the indemnifying party. If any such action is brought against any indemnified
party and it notifies the indemnifying party of its commencement, the indemnifying party will be entitled to participate in and, to the
extent that it elects by delivering written notice to the indemnified party promptly after receiving notice of the commencement of the
action from the indemnified party, jointly with any other indemnifying party similarly notified, to assume the defense of the action,
with counsel reasonably satisfactory to the indemnified party, and after notice from the indemnifying party to the indemnified party
of its election to assume the defense, the indemnifying party will not be liable to the indemnified party for any other legal expenses
except as provided below and except for the reasonable costs of investigation subsequently incurred by the indemnified party in connection
with the defense. The indemnified party will have the right to employ its own counsel in any such action, but the fees, expenses and
other charges of such counsel will be at the expense of such indemnified party unless (1)&nbsp;the employment of counsel by the indemnified
party has been authorized in writing by the indemnifying party, (2)&nbsp;the indemnified party has reasonably concluded (based on advice
of counsel) that there may be legal defenses available to it or other indemnified parties that are different from or in addition to those
available to the indemnifying party, (3)&nbsp;a conflict or potential conflict exists (based on advice of counsel to the indemnified
party) between the indemnified party and the indemnifying party (in which case the indemnifying party will not have the right to direct
the defense of such action on behalf of the indemnified party) or (4)&nbsp;the indemnifying party has not in fact employed counsel to
assume the defense of such action or counsel reasonably satisfactory to the indemnified party, in each case, within a reasonable time
after receiving notice of the commencement of the action; in each of which cases the reasonable fees, disbursements and other charges
of counsel will be at the expense of the indemnifying party or parties. It is understood that the indemnifying party or parties shall
not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees, disbursements
and other charges of more than one separate firm admitted to practice in such jurisdiction (plus local counsel) at any one time for all
such indemnified party or parties. All such fees, disbursements and other charges will be reimbursed by the indemnifying party promptly
as they are incurred. An indemnifying party will not, in any event, be liable for any settlement of any action or claim effected without
its written consent. No indemnifying party shall, without the prior written consent of each indemnified party, settle or compromise or
consent to the entry of any judgment in any pending or threatened claim, action or proceeding relating to the matters contemplated by
this Section&nbsp;9 (whether or not any indemnified party is a party thereto), unless such settlement, compromise or consent (1)&nbsp;includes
an express and unconditional release of each indemnified party, in form and substance reasonably satisfactory to such indemnified party,
from all liability arising out of such litigation, investigation, proceeding or claim and (2)&nbsp;does not include a statement as to
or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Settlement
Without Consent if Failure to Reimburse</U>. If an indemnified party shall have requested an indemnifying party to reimburse the indemnified
party for reasonable fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature
contemplated by Section&nbsp;9(a)(ii)&nbsp;effected without its written consent if (1)&nbsp;such settlement is entered into more than
45 days after receipt by such indemnifying party of the aforesaid request, (2)&nbsp;such indemnifying party shall have received notice
of the terms of such settlement at least 30 days prior to such settlement being entered into and (3)&nbsp;such indemnifying party shall
not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Contribution</U>.
In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the foregoing paragraphs
of Section&nbsp;9 is applicable in accordance with its terms but for any reason is held to be unavailable or insufficient from the Company
or the Underwriters, the Company and the Underwriters will contribute to the total losses, claims, liabilities, expenses and damages
(including any investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of,
any action, suit or proceeding or any claim asserted) to which any indemnified party may be subject in such proportion as shall be appropriate
to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other hand. The relative benefits
received by the Company on the one hand and the Underwriters on the other hand shall be deemed to be in the same proportion as the total
net proceeds from the sale of the Offered Shares (before deducting expenses) received by the Company bear to the total compensation received
by the Underwriters (before deducting expenses) from the sale of Offered Shares on behalf of the Company. If, but only if, the allocation
provided by the foregoing sentence is not permitted by applicable Law, the allocation of contribution shall be made in such proportion
as is appropriate to reflect not only the relative benefits referred to in the foregoing sentence but also the relative fault of the
Company, on the one hand, and the Underwriters, on the other hand, with respect to the statements or omission that resulted in such loss,
claim, liability, expense or damage, or action in respect thereof, as well as any other relevant equitable considerations with respect
to such offering. Such relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement
of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or the Underwriters,
the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such statement or
omission. The Company and the Underwriters agree that it would not be just and equitable if contributions pursuant to this Section&nbsp;10
were to be determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations
referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, liability, expense, or damage,
or action in respect thereof, referred to above in this Section&nbsp;10 shall be deemed to include, for the purpose of this Section&nbsp;10,
any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action
or claim to the extent consistent with Section&nbsp;9(c). Notwithstanding the foregoing provisions of Section&nbsp;9 and this Section&nbsp;10,
the Underwriters shall not be required to contribute any amount in excess of the commissions actually received by it under this Agreement
and no person found guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the Securities Act) will
be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section&nbsp;10,
any person who controls a party to this Agreement within the meaning of the Securities Act, any affiliates of the respective Underwriters
and any officers, directors, partners, employees or agents of the Underwriters or their respective affiliates, will have the same rights
to contribution as that party, and each director of the Company and each officer of the Company who signed the Registration Statement
will have the same rights to contribution as the Company, subject in each case to the provisions hereof. Any party entitled to contribution,
promptly after receipt of notice of commencement of any action against such party in respect of which a claim for contribution may be
made under this Section&nbsp;10, will notify any such party or parties from whom contribution may be sought, but the omission to so notify
will not relieve that party or parties from whom contribution may be sought from any other obligation it or they may have under this
Section&nbsp;10 except to the extent that the failure to so notify such other party materially prejudiced the substantive rights or defenses
of the party from whom contribution is sought. Except for a settlement entered into pursuant to the last sentence of Section&nbsp;9(c),
no party will be liable for contribution with respect to any action or claim settled without its written consent if such consent is required
pursuant to Section&nbsp;9(c).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Default
of One or More of the Several Underwriters</U>. If, on the First Closing Date or any Option Closing Date, any one or more of the several
Underwriters shall fail or refuse to purchase Offered Shares that it or they have agreed to purchase hereunder on such date, and the
aggregate number of Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase does not
exceed 10% of the aggregate number of the Offered Shares to be purchased on such date, the Representative may make arrangements satisfactory
to the Company for the purchase of such Offered Shares by other persons, including any of the Underwriters, but if no such arrangements
are made by such date, the other Underwriters shall be obligated, severally and not jointly, in the proportions that the number of Firm
Shares set forth opposite their respective names on <U>Schedule A</U> bears to the aggregate number of Firm Shares set forth opposite
the names of all such non-defaulting Underwriters, or in such other proportions as may be specified by the Representative with the consent
of the non-defaulting Underwriters, to purchase the Offered Shares which such defaulting Underwriter or Underwriters agreed but failed
or refused to purchase on such date. If, on the First Closing Date or any Option Closing Date, any one or more of the several Underwriters
shall fail or refuse to purchase Offered Shares that it or they have agreed to purchase hereunder on such date, and the aggregate number
of Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase exceeds 10% of the aggregate
number of Offered Shares to be purchased on such date, and arrangements satisfactory to the Representative and the Company for the purchase
of such Offered Shares are not made within 48 hours after such default, this Agreement shall terminate without liability of any party
to any other party except that the provisions of Section&nbsp;4, Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 shall at all times
be effective and shall survive such termination. In any such case either the Representative or the Company shall have the right to postpone
the First Closing Date or the applicable Option Closing Date, as the case may be, but in no event for longer than seven days in order
that the required changes, if any, to the Registration Statement and the Prospectus or any other documents or arrangements may be effected.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this Agreement,
the term &ldquo;<B>Underwriter</B>&rdquo; shall be deemed to include any person substituted for a defaulting Underwriter under this Section&nbsp;11.
Any action taken under this Section&nbsp;11 shall not relieve any defaulting Underwriter from liability in respect of any default of
such Underwriter under this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Termination
of this Agreement</U>. Prior to the purchase of the Firm Shares by the Underwriters on the First Closing Date, this Agreement may be
terminated by the Representative by notice given to the Company if at any time: (i)&nbsp;trading or quotation in any of the Company&rsquo;s
securities shall have been suspended or limited by the Commission or by NASDAQ, or trading in securities generally on either NASDAQ or
the NYSE shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock
exchanges; (ii)&nbsp;a general banking moratorium shall have been declared by any of federal, New York or Delaware authorities; (iii)&nbsp;there
shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the
United States or international financial markets, or any substantial change or development involving a prospective substantial change
in United States&rsquo; or international political, financial or economic conditions, as in the judgment of the Representative is material
and adverse and makes it impracticable to market the Offered Shares in the manner and on the terms described in the Time of Sale Prospectus
or the Prospectus or to enforce contracts for the sale of securities; (iv)&nbsp;in the judgment of the Representative there shall have
occurred any change, or any development or event involving a prospective change, in the condition, financial or otherwise, or in the
business, properties, earnings, results of operations or prospects of the Company and its Subsidiaries considered as one enterprise,
whether or not arising in the ordinary course of business; or (v)&nbsp;the Company shall have sustained a loss by strike, fire, flood,
earthquake, accident or other calamity of such character as in the judgment of the Representative may interfere materially with the conduct
of the business and operations of the Company regardless of whether or not such loss shall have been insured. Any termination pursuant
to this Section&nbsp;12 shall be without liability on the part of (a)&nbsp;the Company to any Underwriter, except that the Company shall
be obligated to reimburse the expenses of the Representative and the Underwriters pursuant to Section&nbsp;4 or Section&nbsp;7 hereof
or (b)&nbsp;any Underwriter to the Company; <U>provided</U>, <U>however</U>, that the provisions of Section&nbsp;9 and Section&nbsp;10
shall at all times be effective and shall survive such termination.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Advisory or Fiduciary Relationship</U>. The Company acknowledges and agrees that (a)&nbsp;the purchase and sale of the Offered Shares
pursuant to this Agreement, including the determination of the public offering price of the Offered Shares and any related discounts
and commissions, is an arm&rsquo;s-length commercial transaction between the Company, on the one hand, and the several Underwriters,
on the other hand, (b)&nbsp;in connection with the offering contemplated hereby and the process leading to such transaction, each Underwriter
is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, or its creditors,
employees or any other party, (c)&nbsp;no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of
the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter
has advised or is currently advising the Company on other matters) and no Underwriter has any obligation to the Company with respect
to the offering contemplated hereby except the obligations expressly set forth in this Agreement, (d)&nbsp;the Underwriters and their
respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, and
(e)&nbsp;the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated
hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Representations
and Agreements to Survive Delivery</U>. The respective indemnities, agreements, representations, warranties and other statements of the
Company, its officers and the several Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect,
regardless of any investigation made by or on behalf of any Underwriter or the Company or any of its or their partners, affiliates, officers,
directors or employees or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive
delivery of and payment for the Offered Shares sold hereunder and any termination of this Agreement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties hereto
as follows:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0; text-indent: 0; width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0; text-indent: 0; width: 2.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to the Representative:</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Cantor Fitzgerald&nbsp;&amp; Co.</FONT></TD></TR>
</TABLE>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in; text-align: justify">499 Park Avenue&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in; text-align: justify">New York, NY 10022&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in; text-align: justify">Facsimile: (212) 829-4708&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in; text-align: justify">Attention: General Counsel</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0; text-indent: 0; width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0; text-indent: 0; width: 2.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a copy to:</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">McGuireWoods LLP</FONT></TD></TR>
</TABLE>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.75in">1251 6<SUP>th</SUP> Avenue,
20<SUP>th</SUP> Floor&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.75in">New York, New York 10020&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.75in">Attention: Stephen Older</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0; text-indent: 0; width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0; text-indent: 0; width: 2.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to the Company:</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Cognition Therapeutics,&nbsp;Inc.</FONT></TD></TR>
</TABLE>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.75in">2500 Westchester Ave.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.75in">Purchase, NY 10577&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.75in">Attention: Lisa Ricciardi,
Chief Executive Officer&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">lricciardi@cogrx.com</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0; text-indent: 0; width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0; text-indent: 0; width: 2.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a copy to:</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Troutman Pepper Hamilton Sanders LLP</FONT></TD></TR>
</TABLE>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.75in">3000 Two Logan Square&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.75in">Philadelphia, PA 19103&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.75in">Attention: Rachael M. Bushey
and Joseph Walsh&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.75in">Email: &nbsp;&nbsp;&nbsp;&nbsp;rachael.bushey@troutman.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.75in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;joseph.walsh@troutman.com</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each party to this Agreement
may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose. Each
such notice or other communication shall be deemed given (i)&nbsp;when delivered personally or by verifiable facsimile transmission (with
an original to follow) on or before 4:30&nbsp;p.m., New York City time, on a Business Day or, if such day is not a Business Day, on the
next succeeding Business Day, (ii)&nbsp;on the next Business Day after timely delivery to a nationally-recognized overnight courier and
(iii)&nbsp;on the Business Day actually received if deposited in the U.S. mail (certified or registered mail, return receipt requested,
postage prepaid).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Electronic
Notice</U>. An electronic communication (&ldquo;<B>Electronic Notice</B>&rdquo;) shall be deemed written notice for purposes of this
Section&nbsp;16 if sent to the electronic mail address specified by the receiving party under separate cover. Electronic Notice shall
be deemed received at the time the party sending Electronic Notice receives verification of receipt by the receiving party. Any party
receiving Electronic Notice may request and shall be entitled to receive the notice on paper, in a nonelectronic form (&ldquo;<B>Nonelectronic
Notice</B>&rdquo;) which shall be sent to the requesting party within ten (10)&nbsp;days of receipt of the written request for Nonelectronic
Notice.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. This Agreement shall inure to the benefit of and be binding upon the Company and the Underwriters and their respective
successors and the parties referred to in Section&nbsp;11. References to any of the parties contained in this Agreement shall be deemed
to include the successors and permitted assigns of such party. Nothing in this Agreement, express or implied, is intended to confer upon
any party other than the parties hereto or their respective successors and permitted assigns any rights, remedies, obligations or liabilities
under or by reason of this Agreement, except as expressly provided in this Agreement. Neither party may assign its rights or obligations
under this Agreement without the prior written consent of the other party; <U>provided</U>, <U>however</U>, that the Representative may
assign its rights and obligations hereunder to an affiliate thereof without obtaining the Company&rsquo;s consent.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Partial
Unenforceability</U>. The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect the
validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this Agreement
is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor
changes) as are necessary to make it valid and enforceable.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Entire
Agreement; Amendment; Severability; Waiver</U>. This Agreement (including all schedules and exhibits attached hereto issued pursuant
hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings, both written
and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement nor any term hereof may be amended
except pursuant to a written instrument executed by the Company and the Representative. In the event that any one or more of the provisions
contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as written by a court of
competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is valid, legal
and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or unenforceable
term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder of the terms
and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement. No implied waiver by a party
shall arise in the absence of a waiver in writing signed by such party. No failure or delay in exercising any right, power, or privilege
hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise
thereof or the exercise of any right, power, or privilege hereunder.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>GOVERNING
LAW AND TIME; WAIVER OF JURY TRIAL</U>. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF
NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH PARTY HEREBY
IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING
OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>CONSENT
TO JURISDICTION</U>. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE
CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH ANY TRANSACTION CONTEMPLATED
HEREBY, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY
SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS BROUGHT IN AN INCONVENIENT FORUM OR THAT THE VENUE
OF SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS
BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF (CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED)
TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND
SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS
IN ANY MANNER PERMITTED BY LAW.</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Counterparts</U>.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile or electronic
transmission.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Construction</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
section and exhibit&nbsp;headings herein are for convenience only and shall not affect the construction hereof;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">words
defined in the singular shall have a comparable meaning when used in the plural, and vice versa;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
words &ldquo;hereof,&rdquo; &ldquo;hereto,&rdquo; &ldquo;herein&rdquo; and &ldquo;hereunder&rdquo; and words of similar import, when
used in this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">wherever
the word &ldquo;include,&rdquo; &ldquo;includes&rdquo; or &ldquo;including&rdquo; is used in this Agreement, it shall be deemed to be
followed by the words &ldquo;without limitation&rdquo;;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">references
herein to any gender shall include each other gender;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">references
herein to any law, statute, ordinance, code, regulation, rule&nbsp;or other requirement of any Governmental Authority shall be deemed
to refer to such law, statute, ordinance, code, regulation, rule&nbsp;or other requirement of any Governmental Authority as amended,
reenacted, supplemented or superseded in whole or in part and in effect from time to time and also to all rules&nbsp;and regulations
promulgated thereunder;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">if
the last day for the giving of any notice or the performance of any act required or permitted under this Agreement is a day that is not
a Business Day, then the time for the giving of such notice or the performance of such action shall be extended to the next succeeding
Business Day;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B>knowledge</B>&rdquo;
means, as it pertains to the Company, the actual knowledge of the officers and directors of the Company, together with the knowledge
which they would have had if they had conducted a reasonable inquiry of the relevant persons into the relevant subject matter;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Governmental
Authority</B>&rdquo; means (i)&nbsp;any federal, provincial, state, local, municipal, national or international government or governmental
authority, regulatory or administrative agency, governmental commission, department, board, bureau, agency or instrumentality, court,
tribunal, arbitrator or arbitral body (public or private); (ii)&nbsp;any self-regulatory organization; or (iii)&nbsp;any political subdivision
of any of the foregoing;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Law</B>&rdquo;
means any and all laws, including all federal, state, local, municipal, national or foreign statutes, codes, ordinances, guidelines,
decrees, rules, regulations and by-laws and all judicial, arbitral, administrative, ministerial, departmental or regulatory judgments,
orders, directives, decisions, rulings or awards or other requirements of any Governmental Authority, binding on or affecting the person
referred to in the context in which the term is used and rules, regulations and policies of any stock exchange on which securities of
the Company are listed for trading; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Business
Day</B>&rdquo; means any day on which NASDAQ and commercial banks in the City of New York are open for business.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>General
Provisions</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the parties hereto
acknowledges that it is a sophisticated business person who was adequately represented by counsel during negotiations regarding the provisions
hereof, including the indemnification provisions of Section&nbsp;9 and the contribution provisions of Section&nbsp;10, and is fully informed
regarding said provisions. Each of the parties hereto further acknowledges that the provisions of Section&nbsp;9 and Section&nbsp;10
hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs and its business in order
to assure that adequate disclosure has been made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus,
each free writing prospectus and the Prospectus (and any amendments and supplements to the foregoing), as contemplated by the Securities
Act and the Exchange Act.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<B><I>Signature Page&nbsp;Follows</I></B>]</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing correctly
sets forth the understanding between the Company and the Underwriters, please so indicate in the space provided below for that purpose,
whereupon this letter shall constitute a binding agreement between the Company and the Underwriters.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify; padding-right: 5.75pt">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify; padding-right: 5.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify; padding-right: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">COGNITION
THERAPEUTICS,&nbsp;INC.&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.75pt; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Lisa Ricciardi</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt; text-align: justify; width: 4%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt; text-align: justify; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt; text-align: justify; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lisa Ricciardi</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify; padding-right: 5.75pt">ACCEPTED as of the date first-above
written:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify; padding-right: 5.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify; padding-right: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CANTOR
FITZGERALD&nbsp;&amp; CO.&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.75pt; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sage
    Kelly</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt; text-align: justify; width: 4%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt; text-align: justify; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt; text-align: justify; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sage Kelly</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior Managing Director, Head of Investment Banking</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.75pt; font-size: 10pt; text-align: justify">For itself and the other several Underwriters
named in <U>Schedule A</U> to this Agreement.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">Cognition
Therapeutics. Inc.. &ndash; Underwriting Agreement</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE A</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Underwriters</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Number of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Firm Shares</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>to be <BR>
Purchased</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font: 10pt Times New Roman, Times, Serif; text-align: justify">Cantor Fitzgerald&nbsp;&amp; Co.&#9;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">4,500,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Newbridge Securities Corporation </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">500,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: justify; padding-bottom: 2.5pt">&nbsp;Total&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,000,000</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE A-1</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Investor</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Amount of Shares to be Purchased</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-size: 10pt; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE A-2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Investor</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Amount of Shares to be Purchased</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-size: 10pt; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Free Writing Prospectuses Included in the
Time of Sale Prospectus</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>None.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Schedule
C</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Pricing Information</U></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Firm Shares: 5,000,000</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Option Shares: 750,000</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Price to Public: $1.200</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Underwriters&rsquo; Discount (other than the
Firm Shares set forth on Schedule A-1): $0.072</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Schedule
D</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Permitted Section&nbsp;5(d)&nbsp;Communications</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>None.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;A</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form&nbsp;of Lock-up Agreement</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cantor Fitzgerald&nbsp;&amp; Co.&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">499 Park Avenue&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10022&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: Equity Capital Markets</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Re: Proposed Registered Follow-On Offering
by Cognition Therapeutics,&nbsp;Inc.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The undersigned, a securityholder
and/or officer and/or a director of Cognition Therapeutics,&nbsp;Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), understands
that Cantor Fitzgerald&nbsp;&amp; Co. (&ldquo;<U>CF&amp;Co.</U>&rdquo;) proposes to enter into an Underwriting Agreement (the &ldquo;<U>Underwriting
Agreement</U>&rdquo;) with the Company relating to the proposed registered follow-on offering (the &ldquo;<U>Offering</U>&rdquo;) of
shares of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;<U>Common Stock</U>&rdquo;). The undersigned acknowledges
that CF&amp;Co. is relying on the representations and agreements of the undersigned contained in this lock-up agreement in conducting
the Offering and, at a subsequent date, in entering into the Underwriting Agreement and other underwriting arrangements with the Company
with respect to the Offering.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In recognition of the benefit
that the Offering will confer upon the undersigned as a securityholder and/or officer and/or a director of the Company, and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees that, during the
period beginning on the date hereof and ending on the date that is 90 days from the date of the Underwriting Agreement (the &ldquo;<U>Lock-Up
Period</U>&rdquo;), the undersigned will not (and will cause any immediate family member not to), without the prior written consent of
CF&amp;Co., which may withhold its consent in its sole discretion, directly or indirectly, (i)&nbsp;sell, offer to sell, contract to
sell or lend, effect any short sale or establish or increase a Put Equivalent Position (as defined in Rule&nbsp;16a-1(h)&nbsp;under the
Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;)) or liquidate or decrease any Call Equivalent Position
(as defined in Rule&nbsp;16a-1(b)&nbsp;under the Exchange Act), pledge, hypothecate or grant any security interest in, or in any other
way transfer or dispose of, any Common Stock or any securities convertible into or exchangeable or exercisable for Common Stock, in each
case whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the
power of disposition (collectively, the &ldquo;<U>Lock-Up Securities</U>&rdquo;), (ii)&nbsp;make any demand for, or exercise any right
with respect to the registration of any of the Lock-Up Securities, or the filing of any registration statement, prospectus or prospectus
supplement (or an amendment or supplement thereto) in connection therewith, under the Securities Act of 1933, as amended, (iii)&nbsp;enter
into any swap, hedge or any other agreement or any transaction that transfers, in whole or in part, the economic consequence of ownership
of the Lock-Up Securities, whether any such swap or transaction is to be settled by delivery of Common Stock or other securities, in
cash or otherwise, or (iv)&nbsp;publicly announce the intention to do any of the foregoing.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Notwithstanding the foregoing,
and subject to the conditions below, the undersigned may transfer the Lock-Up Securities pursuant to clauses (i)&nbsp;through (vi)&nbsp;below
without the prior written consent of CF&amp;Co., <U>provided</U> that (1)&nbsp;prior to any such transfer, CF&amp;Co. receives a signed
lock-up agreement, substantially in the form of this lock-up agreement, for the balance of the Lock-Up Period from each donee, trustee,
distributee or transferee, as the case may be, (2)&nbsp;any such transfer shall not involve a disposition for value, (3)&nbsp;in the
case of clauses (i)&nbsp;through (iii)&nbsp;below, such transfers are not required to be reported with the Securities and Exchange Commission
under the Exchange Act, and (4)&nbsp;the undersigned does not otherwise voluntarily effect any public filing or report regarding such
transfers:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">as
a bona fide gift or gifts;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">to
any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">pursuant
to a qualified domestic order or in connection with a divorce settlement;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">by
will or intestate succession to the legal representative, heir, beneficiary or immediate family of the undersigned upon the death of
the undersigned;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">distributions
to partners, members or stockholders of the undersigned, or</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">transfers
to the undersigned&rsquo;s affiliates or to any investment fund or other entity controlled or managed by the undersigned.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The undersigned further
agrees that the foregoing provisions shall be equally applicable to any Common Stock the undersigned may purchase or otherwise receive
in the Offering.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The undersigned also agrees
and consents to the entry of stop transfer instructions with the Company&rsquo;s transfer agent and registrar against the transfer of
the Lock-Up Securities except in compliance with the foregoing restrictions.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">With respect to the Offering
only, the undersigned waives any registration rights relating to registration under the Securities Act of the offer and sale of any shares
of Common Stock and/or any options or warrants or other rights to acquire Common Stock or any securities exchangeable or exercisable
for or convertible into Common Stock, or to acquire other securities or rights ultimately exchangeable or exercisable for or convertible
into Common Stock, owned either of record or beneficially by the undersigned, including any rights to receive notice of the Offering.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The undersigned confirms
that the undersigned has not, and has no knowledge that any immediate family member has, directly or indirectly, taken any action designed
to or that might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company
to facilitate the sale of the Common Stock The undersigned will not, and will cause any immediate family member not to take, directly
or indirectly, any such action.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As used herein, &ldquo;immediate
family&rdquo; shall mean the spouse, domestic partner, lineal descendant, father, mother, brother, sister, or any other person with whom
the undersigned has a relationship by blood, marriage or adoption not more remote than first cousin.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The undersigned represents
and warrants that the undersigned has full power, capacity and authority to enter into this lock-up agreement. This lock-up agreement
is irrevocable and will be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This lock-up agreement shall
be governed by and construed in accordance with the laws of the State of New York.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The undersigned acknowledges
and agrees that whether or not the Offering actually occurs depends on a number of factors, including market conditions. Any Offering
will only be made pursuant to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and CF&amp;CO.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This lock-up agreement shall
automatically terminate, and the undersigned shall be released from its obligations hereunder, upon the earliest to occur, if any, of
(i)&nbsp;the Company advising CF&amp;Co. in writing, prior to the execution of the Underwriting Agreement, that it has determined not
to proceed with the Offering, (ii)&nbsp;the executed Underwriting Agreement being terminated prior to the closing of the Offering (other
than the provisions thereof that survive termination), and (iii)&nbsp;February&nbsp;28, 2023, in the event that the Underwriting Agreement
has not been executed by such date.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>Signature Page&nbsp;Follows</I>]</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">Name of Securityholder/Director/Officer <I>(Print exact name)</I></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 3%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 47%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Signature</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">If not signing in an individual capacity:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">Name of Authorized Signatory <I>(Print</I>)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">Title of Authorized Signatory <I>(Print</I>)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><I>(indicate capacity of person signing
if signing as custodian, trustee or on behalf of an entity)</I></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;B</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Parties to Lock-up Agreement</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">1.</TD><TD STYLE="text-align: justify">Anthony
                                            Caggiano</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">2.</TD><TD STYLE="text-align: justify">Andrew
                                            Einhorn</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">3.</TD><TD STYLE="text-align: justify">Aaron
                                            Fletcher</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">4.</TD><TD STYLE="text-align: justify">Jack
                                            Khattar</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">5.</TD><TD STYLE="text-align: justify">Brett
                                            Monia</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">6.</TD><TD STYLE="text-align: justify">Lisa
                                            Ricciardi</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">7.</TD><TD STYLE="text-align: justify">Ellen
                                            Richstone</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">8.</TD><TD STYLE="text-align: justify">Peggy
                                            Wallace</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">9.</TD><TD STYLE="text-align: justify">Entities
                                            affiliated with BIOS Memory SPV I, LP</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;C</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM&nbsp;OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CHIEF FINANCIAL OFFICER&rsquo;S CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>COGNITION THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">November&nbsp;[__], 2022</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
</FONT>Andrew Einhorn, do hereby certify that I am the Chief Financial of Cognition Therapeutics,&nbsp;Inc., a Delaware corporation (the
 &ldquo;<U>Company</U>&rdquo;), and, pursuant to Section&nbsp;(h)&nbsp;of the Underwriting Agreement, dated as of November&nbsp;10, 2022
(the &ldquo;<U>Agreement</U>&rdquo;), by and between the Company and Cantor Fitzgerald&nbsp;&amp; Co., as representative of the several
underwriters named in Schedule A thereto (the &ldquo;<U>Representative</U>&rdquo;), in my capacity as such and not in any individual
capacity, and based upon a diligent examination of the financial records of the Company, the scope and nature of such examination being
designed to identify information relevant to the subjects addressed below, do hereby certify that:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">That the amounts and financial information identified in the
pages&nbsp;of the Time of Sale Prospectus and Prospectus under the section entitled &ldquo;Recent Events&mdash;Preliminary Third Quarter
Results&rdquo; with regard to preliminary estimates for the quarter ended September&nbsp;30, 2022 and preliminary estimates for the nine
months ended September&nbsp;30, 2022 (the &ldquo;<U>Preliminary Information</U>&rdquo;) were (i)&nbsp;prepared in good faith and based
upon assumptions that I believe are reasonable and (ii)&nbsp;on a basis consistent with that of the unaudited financial statements of
the Company incorporated by reference in the Registration Statement. To my knowledge, the Preliminary Information represents the Company&rsquo;s
preliminary estimates as of the date of the Time of Sale Prospectus and the Prospectus based upon quarterly analysis, review and reconciliations
of the Company&rsquo;s financial accounts and records, which quarterly analysis, review and reconciliations had not yet been finalized
on the date of the Time of Sale Prospectus and the Prospectus. Furthermore,&nbsp;I supervised the comparison of such Preliminary Information
for the period indicated with the corresponding information shown in or derived from the Company&rsquo;s accounting records and found
them to be consistent and in agreement (except for differences caused by rounding) and nothing has come to my attention that would cause
me to believe that any material modifications should be made to such items.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This certificate is being
furnished to the Representative solely in connection with the offering of the Securities. Troutman Pepper Hamilton Sanders LLP and McGuireWoods
LLP are entitled to rely on this certificate in connection with the respective opinions such firms are rendering pursuant to the Agreement.
All capitalized terms used but not defined herein have the meanings assigned to them in the Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Signature page&nbsp;follows]</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
has executed and delivered this Chief Financial Officer&rsquo;s Certificate on behalf of the Company as of the date first written above.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name: Andrew Einhorn</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title: Chief Financial Officer</TD></TR>
  </TABLE>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>tm2230367d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><IMG SRC="tm2230367d1_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Cognition Therapeutics Reports Third Quarter
2022 Financial Results<BR>
and Provides Business Update</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- SHINE Alzheimer&rsquo;s
Trial Expands to European Sites -&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- SEQUEL Alzheimer&rsquo;s
Trial Awarded Additional NIA Grant to Complete -&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- Over 50% of SHIMMER Dementia with Lewy Bodies
Study Sites Active -</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Purchase,
NY &ndash; November&nbsp;14, 2022 &ndash; <U>Cognition Therapeutics,&nbsp;Inc.</U> (Nasdaq: CGTX), (the &ldquo;Company&rdquo; or &ldquo;Cognition&rdquo;)
today reported financial results for the third quarter ended September&nbsp;30, 2022 and provided an update on the company&rsquo;s business
and clinical development progress.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We continue to advance three Phase 2 clinical
trials investigating CT1812 and are highly motivated by the encouraging data from our clinical programs as well as favorable results
from complementary approaches being pursued by peers in the industry.&rdquo; said <U>Lisa Ricciardi, president and CEO</U> of Cognition
Therapeutics. &ldquo;With the prospect of near-term completion of enrollment in SEQUEL, expanded enrollment in the SHINE Alzheimer&rsquo;s
study, and continued progress in the SHIMMER DLB study, we believe we are entering a period of significant clinical progress.&rdquo;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="background-color: white">Cognition&rsquo;s
lead candidate, CT1812, is in development for age-related degenerative diseases and is designed to </FONT>prevent the binding of toxic
oligomers to neurons, thus protecting these sensitive brain cells. Supplemental grant awards from the National Institute of Aging (NIA)
are supporting the completion of enrollment in the SEQUEL study and the continuation and completion of the SHINE trial. The company is
now expanding enrollment for the ongoing Phase 2 SHINE study into Spain, The Netherlands and the Czech Republic.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Business and Clinical Updates:</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">18
                                            new sites open in the <U>SHIMMER study in DLB</U> with more to be added; all sites expected
                                            to be activated by year-end.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">SHIMMER principal investigator, James E. Galvin, MD, to present Cognition&rsquo;s DLB study design at Clinical Trials in Alzheimer&rsquo;s
Disease (CTAD) conference in San Francisco in November</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Presented proteomic data at AAIC 2022 held in August&nbsp;demonstrating a downward shift in disease-relevant biomarkers including
YKL-40, a biomarker of inflammation, which is upregulated in Alzheimer&rsquo;s disease, towards levels observed in healthy, non-demented
individuals, supporting a positive impact of CT1812 on disease biology.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Cash runway extended into the first half of 2024, inclusive of a $2.14M additional NIA grant awarded for the SEQUEL study.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Q3 2022 Financial Results:</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Research and development expenses for the third quarter ended September&nbsp;30, 2022 were $8.3 million compared to $3.7 million in
2021. The increase for 2022 was primarily attributable to an increased phase 2 trial activity, personnel costs, and preclinical program
expenses.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">General and administrative expenses for the third quarter ended September&nbsp;30, 2022 were $4.4 million compared to $1.6 million
in 2021. The increase for 2022 was primarily attributable to an increase in Director&nbsp;&amp; Officer liability insurance, compensation
and benefits expenses, professional fees driven by increased audit, tax, and legal services, and stock-based compensation expense.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Net loss attributable to common stockholders for the third quarter ended September&nbsp;30, 2022, was $6.6 million or $0.29 per share.
The net loss attributable to common stockholders for the third quarter ended September&nbsp;30, 2021 was $4.9 million, or $8.12 per share.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2230367d1_ex99-1img02.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Grant income for the third quarter ended September&nbsp;30, 2022 totaled $5.9 million.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Cash and cash equivalents at September&nbsp;30, 2022 were approximately $46.6 million.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">As of September&nbsp;30, 2022, a total of $93.6 million of awarded grants remained available to fund our pipeline programs.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Cognition Therapeutics</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cognition Therapeutics,&nbsp;Inc. is a clinical-stage
biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative
disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in
Alzheimer&rsquo;s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and
our <U>pipeline of &sigma;-2 receptor modulators</U> can regulate pathways that are impaired in these diseases. We believe that targeting
the &sigma;-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development
for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at&nbsp;<U>https://cogrx.com/</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-Looking Statements</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>This press release contains forward-looking
statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release,
other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited
to, statements regarding our cash and financial resources and our clinical development plans, are forward-looking statements. These statements
involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements
to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.
In some cases, you can identify forward-looking statements by terms such as &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo;
 &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;aim,&rdquo; &ldquo;seek,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;could,&rdquo;
 &ldquo;intend,&rdquo; &ldquo;target,&rdquo; &ldquo;project,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
 &ldquo;predict,&rdquo; &ldquo;forecast,&rdquo; &ldquo;potential&rdquo; or &ldquo;continue&rdquo; or the negative of these terms or other
similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events
and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements
speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot
be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current
expectations include, but are not limited to: competition, our ability to secure new (and retain existing) grant funding, our ability
to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully
advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related
thereto; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates;
changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive
factors; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic
initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impact of the COVID-19
pandemic on our business, supply chain and labor force; and the risks and uncertainties described in the &ldquo;Risk Factors&rdquo; section
of our annual and quarterly reports filed the Securities Exchange Commission. You should not rely on these forward-looking statements
as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur,
and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry
and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk
factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking
statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm2230367d1_ex99-1img03.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>Cognition Therapeutics</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>Unaudited Selected
Financial Data</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended September&nbsp;30,</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Nine Months Ended September&nbsp;30,</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">(in thousands, except share and per share data)</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2021</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2021</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Consolidated Statements of Operations Data:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Operating Expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 48%; font: 10pt Times New Roman, Times, Serif; text-align: justify">Research and development</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">8,268</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">3,675</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">23,884</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">12,999</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">General and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,357</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,548</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,367</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,791</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,625</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,223</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">34,251</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16,790</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify">Loss from operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(12,625</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,223</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(34,251</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(16,790</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Other income (expense):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify">Grant income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,947</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,037</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18,236</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,375</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify">Change in the fair value of the derivative liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,209</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify">Change in the fair value of the Simple Agreements for Future Equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(932</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,976</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify">Other (expense) income, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">55</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(182</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">256</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify">Gain on debt extinguishment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">443</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Interest expense, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(18</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(894</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total other income (expense), net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,113</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">18,036</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,413</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,625</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,110</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(16,215</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,377</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Cumulative preferred stock dividends</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,859</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,326</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Net loss attributable to common stockholders</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,625</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,969</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(16,215</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(8,703</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Net loss per share attributable to common stockholders, basic and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.29</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(8.12</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.71</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(14.87</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average common shares outstanding, basic and diluted<SUP>(1)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">23,024,026</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">611,680</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">22,684,309</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">585,320</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As of</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>(in
thousands)</B>&nbsp;</P></TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">September&nbsp;30, 2022</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&nbsp;31, 2021</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><B>Consolidated Balance Sheet Data</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: justify">Cash and cash equivalents</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">46,610</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">54,721</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">53,557</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">59,137</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,237</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,864</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(110,219</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(94,004</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total stockholders&rsquo; equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">39,320</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">51,273</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm2230367d1_ex99-1img04.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contact Information:</B>&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cognition Therapeutics,&nbsp;Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">info@cogrx.com&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aline Sherwood (media)</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scienta Communications&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">asherwood@scientapr.com</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Daniel Kontoh-Boateng / Rosalyn Christian (investors)&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tiberend Strategic Advisors,&nbsp;Inc.&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>dboateng@tiberend.com</U> / <U>rchristian@tiberend.com</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>tm2230367d1_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2230367d1_ex99-2img05.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white; color: #1d2228">PURCHASE,
N.Y., Nov.&nbsp;10, 2022 -- Cognition Therapeutics,&nbsp;Inc., (Nasdaq: CGTX), (the Company&rdquo; or &ldquo;Cognition&rdquo;) announced
today the pricing of the public offering of 5,000,000 shares of its common stock, at a public offering price of $1.20 per share, for
gross proceeds of approximately $6.0 million, before deducting underwriting discounts and commissions and offering-related expenses.
The offering is expected to close on November&nbsp;15, 2022, subject to the satisfaction of customary closing conditions. Cognition intends
to use the net proceeds of the offering to fund the development of its product candidates and for working capital and other general corporate
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white; color: #1d2228">Cantor
Fitzgerald&nbsp;&amp; Co. is acting as sole book-running manager for the offering. Newbridge Securities Corporation is acting as co-manager.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #1d2228">A
registration statement on Form&nbsp;S-1 (File No.&nbsp;333-268228) relating to the securities sold in this offering was declared effective
by the Securities and Exchange Commission (SEC) on November&nbsp;9, 2022. The offering is being made only by means of a prospectus that
forms a part of the effective registration statement. When available, electronic copies of the final prospectus may be obtained for free
on the SEC's website at&nbsp;</FONT><U>http://www.sec.gov</U><FONT STYLE="color: #1d2228">&nbsp;or by contacting Cantor Fitzgerald&nbsp;&amp;
Co., Attention: Capital Markets, 499 Park Avenue, 4th Floor, New York, New York 10022 or by email at&nbsp;</FONT><U>prospectus@cantor.com</U><FONT STYLE="color: #1d2228">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white; color: #1d2228">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale
of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such state or other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #1d2228"><B>About
Cognition Therapeutics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="color: #1d2228">Cognition
Therapeutics,&nbsp;Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule
therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our
lead candidate CT1812 in clinical programs in Alzheimer&rsquo;s disease, dementia with Lewy bodies (DLB) and dry age-related macular
degeneration (dry AMD). We believe CT1812 and our pipeline of &sigma;-2 receptor modulators can regulate pathways that are impaired in
these diseases. We believe that targeting the &sigma;-2 receptor with CT1812 represents a mechanism functionally distinct from other
current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline
can be found at&nbsp;</FONT><U>https://cogrx.com/</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white; color: #1d2228"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #1d2228"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #1d2228"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT><I>To the extent any statements made in this press release deal with information that is not historical, they are
forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to,
statements regarding the closing of the offering, as well as the anticipated use of proceeds from the offering and other statements identified
by words such as &ldquo;will,&rdquo; &ldquo;potential,&rdquo; &ldquo;could,&rdquo; &ldquo;can,&rdquo; &ldquo;believe,&rdquo; &ldquo;intends,&rdquo;
 &ldquo;continue,&rdquo; &ldquo;plans,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;estimates,&rdquo; &ldquo;may,&rdquo;
other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different
degrees, uncertain. Uncertainties and risks may cause our actual results to be materially different than those expressed in or implied
by our forward-looking statements. For Cognition, this includes satisfaction of the customary closing conditions of the offering, delays
in obtaining required stock exchange or other regulatory approvals, stock price volatility and the impact of general business and economic
conditions. More detailed information on these and additional factors that could affect our actual results are described in our filings
with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements in this news release speak only
as of the date of this news release. We undertake no obligation to update or revise any forward-looking statement, whether as a result
of new information, future events or otherwise, except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #1d2228"><B><U>Contact
Information:</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #1d2228"><B><U></U></B></FONT><FONT STYLE="color: #1d2228">Cognition Therapeutics,&nbsp;Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><U>info@cogrx.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #1d2228">Aline
Sherwood (media)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #1d2228">Scienta Communications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT><U>asherwood@scientapr.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #1d2228">Daniel
Kontoh-Boateng / Rosalyn Christian (investors)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #1d2228">Tiberend Strategic Advisors,&nbsp;Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><U>dboateng@tiberend.com</U><FONT STYLE="color: #1d2228">/</FONT><U>rchristian@tiberend.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cgtx-20221110.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWauBSbOdzZR+WYkxtmBzbUnKHy8iOw70RSJbTcXWkYwA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:cgtx="http://cogrx.com/20221110" elementFormDefault="qualified" targetNamespace="http://cogrx.com/20221110">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://cogrx.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="cgtx-20221110_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="cgtx-20221110_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>cgtx-20221110_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>cgtx-20221110_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://cogrx.com/role/Cover" xlink:href="cgtx-20221110.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://cogrx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2230367d1_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2230367d1_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !# 00# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WN:3RHRY!
M('7 R:(IDFC5XW#*PR"#D$4]AD8KGM2^U:!*^HVD;S6+'=<VR\E/61!_,=^O
M7JTKZ$RERZG1454L-0MM2M([JTF66&095EJUFEMN---70M%&:IZCJ5KIEE)=
M7<RQQ)U)[^P]31OL#:2NR:>XC@B:21PJCN:?&Q902,9[&L/2X[G59EU.^C:*
M/K:VS=4']]O]H^G:MX<4VK:"BV]1:***104444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4U@&7!&:=0: /-?$,-_P"!
M=1.LZ.N[2YW_ -*M#]U&/\0],_SKH]"\;Z+K<2E+I8)\?-#,0K ^WK^%;FH6
M4-_83VMP@:*5"C ^AKYHNH#;7D\!.?+D9,^N#BO4PM".+BU+22ZGCXJO/"23
MCK%]#WS7?&^C:)"QDNDFG_AAA(9B?Z?C6!X;AOO&=^NO:NNVQA;_ $.T'W<C
M^(^N/6O'XD$DR1DX#, 3^-?3%G;1:?IT5O @6.&,*H'H!1BJ$<+%16K?4,+7
MGBYMRT2Z&'X@\6+I-W'IMA:M?:K+]V!#PH]6-4O.^(.SSOL^E>OD9.[Z9SC]
M:@^', OFU37;CY[JYN63<?X5&#@?G^E=[@5Y9[!SGAOQ)/J\MQ9WVGRV5];8
M\U&&5.>X-'B/Q7#H;Q6L,+7FHS_ZJVCZGW/H*Z$J!D@#)[UP/@F)=7\3:[K=
MP-\R3F"+=_ OM^&!0!9$_P 094\\6VE1@\B!B=WTSG%7= \7F_OVTK5;1K#5
M$&?*8_*X]5-=3@5PGQ+MQ;Z?9ZW!\EY97"[7'!*GM^8'ZT =O<7$5K;R3S2+
M'%&I9V8X  KBD\4^(?$,K_\ "-Z="MDC%?M=WD!S[#_]=-^(=U-/HFF6,;%!
MJ%Q&CD>A[?F1^5=G9VD%A8PVMN@2*) JJ/04 <;-X@\6Z!^_UG3+>[LAR\MF
M3E!ZD'_/O7:6MRMW:0W$8=5E0. ZX(!&>1VKG7\?^%P65]17T(\I_P#"M[3]
M0M=4L8[RRD\R"0'8^",X.._N* .=T#QBFH:_J6BW>R.YM[F5(2.!(BL1C_>
M%=9GCBO*]'T%-<UGQ<$D,%Y!J'F6UPO6-]\GZ'O79^&=?DU*.6QOT$&JVGR7
M$7][T=?8T -T+Q!=:GXCUK3IHXUBL9 L;*#D@D]?RI-6\075CXOTG2(XXS#>
M!B[,#N&,]/RK*\(?\CSXJ_Z[+_,T>(_^2F^&_P#<?^M &OK5QXKBO@NC65G-
M:[!EIGPV[G/<<=*YRY\4^,K76K;29=.TX7=PNZ-0Q((Y[[O8UZ-7!:[_ ,E7
MT'_K@W_L] &EI]UXU>_@6_T_3X[4M^]>.3+!?;FI[KQ!=0>.+/1%CB-O-;F5
MG(.X$9_PKI*X;4/^2N:9_P!>;?\ LU '7ZAJ%MIEC+>7<HBAC&68_P">M<=!
MX@\5^("9]$TZWMK+/R37A.9!Z@"F^.\ZCK^@:&[$6]Q-YDH_O 'I_/\ .NYB
MB2*)(XT"H@PJCH!0!Q+>*M?\/3(/$NG1&S=MOVNTR0I]Q_\ JKM8+B.YMTFA
M</'(H967H0>]1W]E!J%C-:7"!XI5*L#[UR/PTN)3HUY8R,66RNFB0G^[U_GF
M@"UX>\8IJ6N7^CW96.Z@G=82.!(@/\Q769XR*\LT;04UN^\3!',-[!?>9;3K
MUC?+?H>]=EX9U]]2CEL;]!!JMH=EQ%Z^CK[&@"+0?$-WJVO:[82I$B6$H2)E
M!R>6'//^S5@ZGJT*.&M/.;82K)&5&06X(R?X5S]2!WK"\%\^-/%O_7R/_0GK
MN]H]*  '(YHI>E% !1156_O[?3[22ZN91'#&-S,:!-V*'B?7(=!T.XO)&&\+
MMB3^^YZ"O ['1=6UIWEL[&>XR26=5XR?<\5ZO'H-UXTU)-4UI'ATV/FUL3P6
M']Y_3/I7;V]K#:PI#!$D<:#"J@P!7HT<2L+&T5>3/,K89XN5Y:16Q\X:AH6K
M:1M>]L9X!GAV7C\QQ7N7@[7H_$'A^";<#.B^7.OHP_QZUO3VT5Q"T4T2R1L,
M,K#((KA;CP[<^#M4;6=#1I+!O^/NR!R0O]Y/IUQ3K8E8J-IJTEL*CA986?-#
M6+W(=$NQX)\17FCZB?*L+N0S6MP?NY/8G\ORKT#[5!Y/F^='Y>,[]PQCZUGO
M!I7B;28S+''=VLJ[ER.GT]#6&/AIH._K=^5U\KSSM_QKS3U$TU=&UIOB33=7
MU"YL[*;SGMP"S*/D/T/>N2@N/^$(\97B7F5TK5'\R.;'RH^>A_,_I7<:;I5C
MI%L+>QMHX(_1!U^I[U)?:?::E:M;7ENDT3=5<9% QR7=O) )DGC:,C.\,",?
M6N!\2WJ^,M8M?#^EMYUK%*);R=>54#MG\_QK3;X::"9,K]K2(]8EG.T_UKH]
M+T>PT>V^SV-LD,?4[1R3ZD]Z ,/QOH4VJ^'E%D#]ILW$T*CJ=O8>^/Y59\->
M*;+7K!,RK%>(-LUNQPRMWX]*Z$@$5SVK^"=%UBX-S-;&*X/66!MC'Z^M $'B
MMM#L/#NH><EE%-);R)$-B[BY4@8[]<4_P%$\/@G3DD1D?8QPPP<%V(IEAX T
M*QG6=K=[J5>C7+E\?ATKI]H"X H X7P)@^)O%_\ U_\ _L\E:OB?0KB>2+6-
M)Q'JUIRGI,G=&_I6IIFA66E7E]=6J,LM[+YLQ9LY;)/'I]XUI'&.: /.OAY>
MG4/$OB&[:)H6E9&:-NJG+9%6_$?_ "4WPW_N/_6NJMM(L[/5+K4+>/9-=!1+
MCHQ&><>O-,N]%L;W6+34YD8W5H"(F#$ 9]1WH U*X+7?^2KZ#_UP;_V>N]'2
MLRYT*RNM:MM6E1C=VRE8V#$ #GM^)H TZX74/^2NZ9_UYM_[-7=#I6;+HEG-
MKD.L.C&[BC,:-NXV\]OQ- '/>/=-NWBL=:L$+W.FR^9L Y9.,_R_G6YH?B/3
M]>LDGM9TWD?/$3\R'T(K6P",$5S.I> M#U&Y:X\A[>=CDO;OLS^'2@"3Q/XI
MM-"L7"RK+?2#;! ARQ8],CTJ+P+HDVC: /M0Q=7+F>8'L3T'Y5/I'@O1=&N!
M<06QDN!TFF;>P^GI70=.G6@#AO ?_(<\4?\ 7[_5JT_$VAW$TD6LZ21'JUH,
MKZ3)W1OZ5J:;HMEI-U>3VJ,KWDGF2[F)RW/3TZFM+K0!YS\-[MK_ ,0^)+MH
MC$TTB.8VZJ27XKT>L^UT>TL]4N[^"/9-=A1-CHQ7.#CUYK0H **** (YI5AB
M+L<*.M8ZZ;)JMY'>:DO[F([K>U/13_??U;VZ#ZUMD ]1F@#%-.Q+C?<15QVI
MU%%(H*1AD8I:* ,)=/?1;U[FQ4_8YFW3VZ]$;^^H_F/\G:1@R@@Y!'6G$9H
MQTIMW)4;;"T444B@HHHH **** "BBB@ IDJ"2)T)(# @D'!%/I#TH XRWT*"
M?Q+>V@O-1^S6UO$2/MLF?,8L>N?0"F_;K^QU;6[FRM!<V]E'%$6FG(X1-Q X
M.6^;O72V6F_9+Z_NC(7>[E5SQC: H4#]"?QJH= )TC4K'[1AK^21WD"]-_MG
ML,"@""Z\4(LEO;VOV?SYH%N&^U3")8T;ID\DD^@]*C7Q67TF*ZCM?-N'N_L9
MACD# OGG:W0C'.:GN_#TQO\ [987,,+M$L4B3P"52%S@CD8/-66T5G?37DG!
M-G(9&Q&%\QBI7.!P.M %:]UF^L+6!KD:;!<2$[DFNBH [8.WGWXXJ!/%,DFC
M6=Y'9^9/<7)MEACD!!8$@D-CI\N<U:O-$NY=8>_M;V.'S85B=9(?,( ).5Y&
M.OOVK*FT&ZAFT73;2X=/L@EN#=>5E=_;<.G.X\4 :(\0S64MU'K%O';&"#[2
M'BDWJR9P1R!SG'YU#:^*7EOK.*:.T$5VVR,0W0DD0XR-Z@>W8\5.?#;7=O>?
MVC=FXNKJ,1M*B!!&H.0%7)[\\]:FT[2;VVF#W=U;3*JX416JQGZDY)S],4 1
M'Q$W_"/W&J" ';,T<2;O]9B38#GWJ&XU'66\4-9V45L\$5LLCK)(5Y8]?NGD
M;3Q4<7A6Z6&&SDU/?807 GCB$(#'#;MK-GGGV%:+:3=IKSZC;7B1Q3*BSQ/%
MN+;<XVMD8Z^AH K2ZI;VVK:I=3HZK8P1JSAR=Q;+;0O3/3GKS4T.I:LH:>]T
MV.&U$;2?NYM\BX&<%<=3[$TDOAU)[;5(99WS?RB7>HP8R H7'KC:*D@L-8$4
MHN=61Y"FV-H[8*%/]X@DY/Y"@"#1-<N=79)!'9&W==Q\FYWO'Z!ACK^-;]86
MG:#-;ZJ=2NYH)+CRC$OV>#REP2"2W))/ ^E;M !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !28%%% "T444 %%%%
/!1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2230367d1_ex99-1img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2230367d1_ex99-1img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !# 00# 2(  A$! Q$!_\0
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M/K:VS=4']]O]H^G:MX<4VK:"BV]1:***104444 %%%% !1110 4444 %%%%
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M0M=4L8[RRD\R"0'8^",X.._N* .=T#QBFH:_J6BW>R.YM[F5(2.!(BL1C_>
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MU%%(H*1AD8I:* ,)=/?1;U[FQ4_8YFW3VZ]$;^^H_F/\G:1@R@@Y!'6G$9H
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MG:#-;ZJ=2NYH)+CRC$OV>#REP2"2W))/ ^E;M !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !28%%% "T444 %%%%
/!1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2230367d1_ex99-1img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2230367d1_ex99-1img03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !# 00# 2(  A$! Q$!_\0
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M/K:VS=4']]O]H^G:MX<4VK:"BV]1:***104444 %%%% !1110 4444 %%%%
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M0M=4L8[RRD\R"0'8^",X.._N* .=T#QBFH:_J6BW>R.YM[F5(2.!(BL1C_>
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MU%%(H*1AD8I:* ,)=/?1;U[FQ4_8YFW3VZ]$;^^H_F/\G:1@R@@Y!'6G$9H
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MG:#-;ZJ=2NYH)+CRC$OV>#REP2"2W))/ ^E;M !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !28%%% "T444 %%%%
/!1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm2230367d1_ex99-1img04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2230367d1_ex99-1img04.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !# 00# 2(  A$! Q$!_\0
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M/K:VS=4']]O]H^G:MX<4VK:"BV]1:***104444 %%%% !1110 4444 %%%%
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M0M=4L8[RRD\R"0'8^",X.._N* .=T#QBFH:_J6BW>R.YM[F5(2.!(BL1C_>
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MU%%(H*1AD8I:* ,)=/?1;U[FQ4_8YFW3VZ]$;^^H_F/\G:1@R@@Y!'6G$9H
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MG:#-;ZJ=2NYH)+CRC$OV>#REP2"2W))/ ^E;M !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !28%%% "T444 %%%%
/!1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm2230367d1_ex99-2img05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2230367d1_ex99-2img05.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !+ 1L# 2(  A$! Q$!_\0
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M:O*K^T?X9>([>]L'?^P;Z39/;DY$3'N*[SQ/KT?A[P[<ZFP#F-?W:_WF/04
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MM9E(!^;M0!Z)7G$'_)<KG_KS'_H->CUYW!%+_P +ON)/*D\O[&/GVG;]WUH
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MC62*12KHXR&'H16=I5G/I7^@[VELE_X]V8Y:-?[A/<#H#Z8K6<U4]Y_%^?\
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<[CFM.QL;?3;**TM(A'!$NU5%6** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140495753254256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 10, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 10,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cognition
Therapeutics,&#160;Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001455365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-4365359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2500 Westchester Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Purchase<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">481-2210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CGTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>tm2230367d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cgtx-20221110.xsd" xlink:type="simple"/>
    <context id="From2022-11-10to2022-11-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-11-10to2022-11-10">0001455365</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-11-10to2022-11-10">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-11-10to2022-11-10">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-11-10to2022-11-10">2022-11-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-11-10to2022-11-10">Cognition Therapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-11-10to2022-11-10">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-11-10to2022-11-10">001-40886</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-11-10to2022-11-10">13-4365359</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-11-10to2022-11-10">2500 Westchester Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-11-10to2022-11-10">Purchase</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-11-10to2022-11-10">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-11-10to2022-11-10">10577</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-11-10to2022-11-10">412</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-11-10to2022-11-10">481-2210</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-11-10to2022-11-10">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-11-10to2022-11-10">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-11-10to2022-11-10">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-11-10to2022-11-10">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-11-10to2022-11-10">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-11-10to2022-11-10">CGTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-11-10to2022-11-10">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-11-10to2022-11-10">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2022-11-10to2022-11-10">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MIR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%
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M)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%
M  @ !T!N520>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>
M+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2
M*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+B
MRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#
M!!0    (  = ;E5ED'F2&0$  ,\#   3    6T-O;G1E;G1?5'EP97-=+GAM
M;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL
M>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE
M@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J
M1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;
M&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=
M560C2&2FKW@ALO7L^T%.6X.^D<WC_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^Q
MO-9.&G_FB^$_7G\!4$L! A0#%     @ !T!N50=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  '0&Y5
MW);)L>T    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    "  '0&Y5F5R<(Q &  "<)P  $P              @ '+
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  = ;E53DU*8@ 0
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M2P$"% ,4    "  '0&Y5)!Z;HJT   #X 0  &@              @ 'G$0
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  '0&Y599!Y
MDAD!  #/ P  $P              @ ',$@  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     "0 ) #X"   6%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2230367d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cogrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2230367d1_8k.htm">tm2230367d1_8k.htm</File>
    <File>cgtx-20221110.xsd</File>
    <File>cgtx-20221110_lab.xml</File>
    <File>cgtx-20221110_pre.xml</File>
    <File>tm2230367d1_ex1-1.htm</File>
    <File>tm2230367d1_ex99-1.htm</File>
    <File>tm2230367d1_ex99-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2230367d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm2230367d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cgtx-20221110_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cgtx-20221110_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cgtx-20221110.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "cgtx",
   "nsuri": "http://cogrx.com/20221110",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2230367d1_8k.htm",
      "contextRef": "From2022-11-10to2022-11-10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://cogrx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2230367d1_8k.htm",
      "contextRef": "From2022-11-10to2022-11-10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001104659-22-117755-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-117755-xbrl.zip
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M9)F4[5O$&-?MK6>LL!A;%%'=O]KPH6$*71<\)%<Z9F 6>K!*A(W'/>7Z97
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M.<K_-FP:R.+6:+BYIE[^ 5!+ P04    "  '0&Y5Y'U0^?\*  !LAP  %0
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M!(NDR]Q28#?9)J&M"8@&JS& B+VV>"[5&Q5ST4IQG%[2F&Q_(CNP;(;.+1>
MS388FB@@,NS. #0J,2K42,B]P7'+DS7FNT42]70;IM M'I#1-A^Z*B!  &L
M(94:+2[GOGN5>[R]C 6PR4-2/E_>0PJH=PM,C^TV-X X('RZ'0(4B2#4CO(-
MTR6-&']FC<<EYFPC&L/=G,7PB*4GRBU8@XK0QJLS)"#(AO@$4&N%?BB?:4%,
MS@TJ,D R!V_4G<6Q.%A9]><JH60*'@.KUBUA'7;;7%F$ =$$NP,8JI0?U <D
M8] -#0F<V1N*._,/SFPH.+.@P9F]!YS[5Q80.$=O*.Z1?W".AH)S%#0X1^\"
M1U2^]S9G+C[>\'OV:GO@&U1ZP<:T:H5F+PL/&<-;'S R0(YO9(AO5(K!U@V_
MY>PEH1$\C(;D7J !3%O)T;3AX6,WV,=0/4A6<;Y!J@;KO5\6)?/3VK1-VIN:
M4A,>*&UCO8U,J?:-Q2W+<IS^.WGN/$FWB[T@8C5L!:6E# \7F[T^:,H8)()\
MG717V,H;(-;I:EJZNRG'%EO[*<>-Q"! L#DRIQR75U=*D8^JEJQR@H&6H9WL
MK*(MINIZ;J2%4<VF(:.6B^^WT/CZ0LN59=+;1T;AAPM,B:O:ALRI&M?3@ZAU
MP)1>\X4,%3J/5^[E"A>9O2EOI#GKZ74[=<>N$H*H8=V-T6VK= \U^BM/<K'W
M.5NO-[2Z,V1[!A'0N:KI3INJUJVB( CH<J;34&E16^P!C05+DRC)$[KZ69R<
M\@3;2F83N8("-JB(,!5!X #:TEG8"Y%2>@#AEA,)(Q&544PXE(L<\9N'!VOO
MWR5V!4:_804(K P"E%Y[.C B8!PU(E 9@HH8_^A<9MF&\#<!9 GQA!%H'H#)
MT(>(%&2R%ZPRT#=?"Q)M1'^YF\Z6]TF>VDX\38FS_@DP5_=.6GH0? "F=!Z*
M-,0>T'3VU^7?D(KR@, UN^=8+FJ[V*V7+ 56PK*J7('085&Q8)$$@0/L2R?B
MFJ%*BDJMKY6R6H8M1=+274%@M:6JOY481,7;'!F-0*N^/3;_Y]OH41@CP&0'
MN\QU-V SJ7<%34T0&'08,TY6*BE26E^3'?9=V*I_4+#R-BA8]0P*5B$."E9#
M!P4KKX,"M>MRF1+11MTLTV2%@443.]6NP>BPK#-BD0:%"^P/;#OJ$+2/\;':
M9K'LFGR5 %\7'B[$!TM) 9VS]3:[;-8+;MI$07#2Y<Q8<K-<"*\A1E+M@XU-
MG.0D+@U=)!33*,%IO72C[>IY?X@S8@::K^'IT8?!T3"3!E)EF%ICL0[<+\/I
MX[)[^1#'KR1-?Z+LE2X(SA@E<7F]Q79WJ5OO]JF;'MOM!V\ <1!(#7$(/'XC
M@\9/,@JIL.IJF3>:OK)T0W/,BSGLW-9" 3JW]  VV]1HHH!HL3L#**G%J%3[
MFQ1>KEY1#[S*=R:!A83DCJ>(=YK69HI;M0%QTVD0FC=>K3FR'R^741ZG<^9$
MONLB>2&?<8XK?V"9(;GK"9Q=IO69FS9M0!AU&@3G:M8Q<KD:K+CRNFP-GXOA
MUXIU/'VNJ=PO7F-8-->OJ24!(6+SU;&*#4=*ZXV'Q1JGZ:=-EE"2P9V2IG++
M@]5BFX>6)" >;+X '@HI4EIO/)RO"5^)[NY'SE[SQVH-6;!\@-HM'YV6VYQ8
MI0'QTN4/X$:%H#)&+?OK#Z#M?@'T<@5(N+06J6-T0+,:-X8N)&@@<P8Q*8GD
M]9AKEJ-[AKYD!.6/!)U7K]5KKEQ?YN/S+2E1)"=<E*-U&F-NPZA+[/R-*:!A
MX[TIAC((F'KMP>]0J2.0"O% SHU@F3?/\0HCESE9@S,I^D-<4334O&*I3Q\$
M40--ZEP58>T3[R(0R4C?JRHU%^2'AWTMD>/1LL6@-EAN*(+@!+0%#96;[S?P
MMY[?9IDFT47*,'P5IJ5QO(J?:4];P&\O"(@"TQ6T;%\A1(72&P.?,'WBF^<\
MVMUR%A$BG];*ZI:K[QK=P&BWW+RI2&VB!H4&Q-I;_ (4[K- C3P^-'HOWQ?\
MY,/H<H4Y%CTM'K$XB#>;/),]JC '7S'O#')\*V)  ;0;$AT1 >$WP"9T<Z*(
M1$7H!U0&HT:TQ_.V;+\Z(8D_[>[( ^%R3L,]V>:?Q,Z>.LX\!L2Z/JL;7!S]
M)*\W, @0W^H6.@7,4#,#M)3/F559H-]D)JC(Q?:>]N:F*_%);%:;Q*\ESHC8
M\E]02P,$%     @ !T!N51C8&*U3!P  NU@  !4   !C9W1X+3(P,C(Q,3$P
M7W!R92YX;6S-G$USVS80AN^=Z7]@U;,D4T[36K&;L14KHXD3NY:3M+UD(!*2
M, 8!%0 MZ=\7($5%'P2XOF3M@RV3"V#?9R&02P \?[O*>/1$E6927+3BSDDK
MHB*1*1.SB];G<?MR/!B-6I$V1*2$2T$O6D*VWO[Y\T^1_3G_I=V.AHSRM!^]
MDTE[)*;R3?2)9+0?O:>"*F*D>A-](3QW1^20<:JB@<P6G!IJ3Y0-]Z/?.O'K
M2=1N ^K]0D4JU>?[T;;>N3$+W>]VE\ME1\@GLI3J47<2F<$J'!MB<KVM[61U
MLODIBY]S)A[[[M>$:!I97D+W5YI=M%R[FV:7IQVI9MW>R4G<_?OCS3B9TXRT
MF7#<$MJJ2KE:ZLK%9V=GW>)L97IDN9HH7K5QVJW<V=9LS[* _8XGFO5UX=Z-
M3(@IPM[83.2U</^U*[.V.]2.>^W3N+/2::N"7Q!4DM-[.HW<7QN];:N)G*F5
MBU;7G>D.I.V-ULVBS%S1Z44KF9F5K;K7B^/XQ%7\ZYZ162]LK]3,=:I6U-UK
M=*&HIL(4.F_L@;TB=&5L7Z)I59%K'^268<99;KI)'+5=G\HSVY#]6%INO*C\
MX#+9:YH[]O) 9]6/"\*:)IV9?.JFE%G2O?B_5^YCN_Q80+#_?BL:NYQHHTAB
MJMHXF5!>M/'-VAR8='^09Q61!UMKO6/[%H=^[4;N4B615"E5EGE5%U')7KR.
MN^;&HKL@RE;43N:,;T,]53+S$=K0D!Y'=V'9)GX<T4OK0^K\&'(RJT=Z8 )D
M&F- K56#2?4=U8EB"\>F >Z>)9!Q#Y5QC38$U-7WZ)[.F//9N>,NOM0=#(\1
MGB) ^*>8HT90+6(4+H7(";^G"ZD:X.]; IF_PF1>IPT1]5\Y488JOH;0/C(&
M O\-$[A'(2+S!T6$9HX1!/JQ-9#Z:]0;$H]&1.SC.>7<)7A$@'I[G3T0_>^8
MZ/TZ7PC\ZR=WW;>7&SC_G2+ $/SQ4D)PI!8Q"G=4,9G:2[T"\#\R!I(_PR3O
M48C._%JD4.);4W".A _\0!XB[B'3">&E5T-[3(>1UYA#L:/DIHTRT='_0XD"
M@]\QAF)'25<;)") '^1*[3D4'&'\UE#L*(EJDT@$[M?",+-VLP6?\FSR_<'K
M/N]C*RAGE.34)PJ-;_5D0A@W$1)B?&@)Y8R2DX;$H;$>6$V*\)%(Z>H#78=@
M'YE"::/DHD%Y:+CO%,N(6H]9TCR '-M"@:-DH&&!:,0?R&J46F5LRLIIQ6;P
MWB)0_BCI)T@N6AA&(I%J(7<>-P]D;K^;ZX%,@T-\0T%H2%#RTF=(1PO,99I:
M9'KSYX8)&H?"46L.GFO""T) Y@M"WWL>^AX</4J^VBCS!:$_?1[Z4SAZE)RU
M428V^H']>*L>Y-(SJ^TUAF)'R5D;)&)#+ZX^M^I.R2=6KKIJ(G]4 HH?,94-
MB\6.P>;B#^GUE264.6):6R\.F_6=U(;P?]FBZ2ZSWA[*'3'!#0G%>#!9QM\]
MY/ M5SHP@3)&R6EKY6!@=9%6E/B[\;X%%"I*HEHG!H'IC71S*',I@L]RCZV@
M;%$R3I\HC('8K6+6WF%@YS1XM1S*,'LH P'E5\6,]6(@LRP7F^<ZGADVCRD4
M,4J:&)2'@'LL.4N886+VT=Y!*D9X/>LZ.RAHE*30+PR!\IVB+N+4WIH7:\;<
ME@=U.YWZ1N*0/90Z2D[8+!2?_DCKG*KGQJ"F%#02*.DA5#3&F$.3W Z#Z[@W
M>7"[>#PCSI$5E#=*:N@3A<#WDWQ0Q.T>'*^SB>3^K2JUAE#**(E@0!H"Z#U?
MZA$?F$#AHF2 M7(0QX?K53(G8D;]*R/J+:&043+"D#C4L7@&&HMGSQR+43)#
MGRA$ON7Z=/OMNIUP-B/^'6[! N!]/YC4 U(Q]A86VY#<7G.5%;X,[8=Z]!Y3
M*'2<+9PA>1BX\Y09FI9N#9D@(K&IUW;/G2>3;RX%#0+.'D^@:+0I@J^4\P]"
M+L68$BT%3<MT(#1+X"T"C03BG&2#7+0P?)$\MZ14L0!5>;X+'E,H=L2Y2(\\
MO/6>Y:+J[?6H?,E(B+JO!!0^XJ1D6"SB6CA#G=_LB;XCAFR\#,7 5P(: \0)
MRK!8U#7\:F O1C,9GHL_,(021UR"6RL-#?0X(YQ?Y9H)JH/CS($A%#3B6MM:
M:6B@KS.J9G:0>Z_DTLPW^T]#P#T%H. 15]0&I>(%8/5]WWNY-R](O\8:_$8%
M1/1>D9BO#$D2MU"CO,*+E"@/^9 ]E#WJQD^_4 3ZMV9.U>Z]5>'0R.9WH045
MS:6@D4!):Z&B\:ZW.V\?"%YN]^R@S!$3V#IA>/NX\@EGR9!+$KQOWS.#,D;,
M5FMDH2&^(N)1Y0N3K.^43"AUTS!Z^\T#)$W "J!A0<QCGX4"[]&"S#*WP4DF
MC^.Y%:YO<U.\G]7Z&'S $"P'#0_F)E. <,2[(_U] QI-K];W=$J56P+Q0%?F
MRC;V&+Y9 A2'Q@CUS4A@##6A.N\>Z;JQ!]Q;>,LS[I=[TZP]\C]02P,$%
M  @ !T!N571[3\+C%@  [G\  !(   !T;3(R,S S-C=D,5\X:RYH=&WM/6M7
MVDK7WUW+_S OYSEGV?4() $4+^59BFBIBA90VWYQ#<D T=S,1<!?_^X]DT"
M<-&BM>TY/:V2N>P]^[[WS(3]__5-@SPRU]-MZV-*SD@IPBS5UG2K\S$5^.UT
M,?6_TOK:?M>'?M#7\CZFNK[O[&:SO5XOT\ME;+>3E7=V=K)][),2G7;[B?T4
M29*S7\_/&FJ7F32M6YY/+94-!QFZ=3][?FP==FVYAC[6%9]$0'+9J:FA51L-
MB'?>RHK&L:Y^8M>"Z.I'777/SBOR]CP\1(_A@/ZLOC+B#"MD7P_K9Z/N?G+_
M4=>L[U++:]NN27W@(<Y42$M*6MF*39+VF#HV$7S.=.S'A?,4TSDYFF>*.>,K
MQ>86]884U]@$N2.8T  C%/DA'W5U67OFQ%M9:(TZ!EZZ0ZDS[-RF7HMW#!OX
MO&E)CF$-+:YM,"]Q#&])&*3:@>6[@V3\PT8^+!K@N?XT 'B8-'?''PF!:G?<
M?D:U3>RHR+(LI;BV,:K!3X+_[?NZ;[#2?E;\A%:3^93@!&GV$.B/'U-EV_*9
MY:>; P?(KXI/'U,^Z_M9H919')<-I]W_OW2:'.O,T'9)@_E[I$9-MDOZ6G^/
M5(_X+[>2<G![U?A;.3HY.+B$'[@.DDXO.SJGW.(Z;X?KNXW6]XQ)\H7AJ)<,
M+Y1O&<@:( __5RP@WZ ,='&I4;4TUC]E@UL)[%&^4,AM%9XS[TYLW@.361K\
M]8\-VKEM4\-CSYAJZQ"(?'0KWX9F0LP)CYXSAW+;Z%*7>;?*+;>*8A*//WO.
M/$>(RV4X5VX*I9F3MVQM0#Q_8+"/J3;(WBZ1)<<G3=V$+C76(W7;I-:F>+ )
M"+AZFTNYIC]&XS3=<PPZV"66;3'>J/=W45R9BWK /^F:QBRN%?@1.M8"$^92
MA<#W_3I:D6/7-E%6TK*<EB7?'OV>(A:L&D Q?3=1&E*ED3CL9\= K ;JF*RD
M2EQ8$@%EQY:+<,$&,A<<,_-$#S2VNQ[WHH  X:YQM\OM*.I=.E*73-_34F&S
M#];A8\K33<=@PB*$H,8G%^ \.W C:-"-\WXW7#+1M;E+CBQ7-(QQ:@^?#I_K
M&K:T=>82OA26Z*+*U=-QSDP.'H'+)L(+H3E 7UN;Q@+B!-<_HCXKC980S31J
MFQH&K)PQ*&J91&L,@>AA2-)Q.@>6+H@,:C=%39-1+W!9*=3/7>@3318UC8/
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M63/"=?G[X_76]^*)>;?J-8Y ITJ0=D/H/+TU$"YIDTPNII"T&&Y,+]Q+B+C
M8LX(].0!]:]I\>;ID:YZ11/P(8G\]EK1@O3,<&%B?#[_ZDHE)W'HTH:8V/BN
M.[,#<?6LX"B.VSIB;-7\&8,.L8)4V-[^-<*$< &8@3HNR);N4(.P/E,AL7W$
MQ!3\"O-^06<)S"#(C5?WA<EHOTFY952>^.>OHB)O[WG0S6!.U[88L7B8LTF
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M\7KI6\0$<\!?X 6$B0NNF^MKPXN39.S>),$KDV0#O2:>8(00JAR%D?!)WOM
M>(+),P"D>>ASK["6W'/Y]JYX,J2[^!B?<6YG 24,#\K@WR$T.-;]IPX>>-+(
M/]2$C+=L9S8Q&W&9XS(/QM'P;"QW]QY[Q,YB QGA,-?C?I*G+?AR-@WL,CG
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M%PY#)S$\83X,,2!ZX,3CT0ZGK= PP/XA "&+O]0"[ZU"2#3@NC9\<5YH>Y;
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MLFKEA90LT;R]_:TG0K;T@3VY2T+!9@5)L4K:<77I+&,42C+"IUF+]_J><%.
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MH>YU-G94E:<5OJ.VW5PTQL<K%J"#;WCAL:#RE,ZS ZQ@/9=0:R 1N%1Y>1\
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MFZ-'P=1P[=T?KG@]*?.%8@1@?(JXBJ1A'74]^WQ"<>!8BTVC*-/]0#$)$"Q
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MIOT [3/.D)DX-2<-8G=,"R+[-)*^)-=Y47)I_7J="Q,"WFWBSM#%5,3V85?
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M$@Q(PMF269;)YSB'ALU<S:J;EQOQRPDD:G7,2":J&=\K0"XR\GW7=UNE#Z
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M^,X&K>'>N*BU=9(4.JF@4=+(TNX8\:0A*M,5N?B1&KB[A(GD0.B$$\,]WJR
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MF&N]EWL[S4;;>I^8@Z[^:2>2HAV0V)V:5LD79P\PW_GJ_([01$O8)54!E0J
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MN(7@7 /J9[J$K0 ZCZEQ7&Y8RD\NJD3*B-:X$)2SZ/?+$CXHGC53>BBJ G;
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M^_[KX)3]#*^"8P4*\[$?]@]\\O[\]O3P=[JAO;_\< S_^#]02P,$%     @
M!T!N5<;.CD#@&0  Q?(  !8   !T;3(R,S S-C=D,5]E>#DY+3$N:'1M[5UI
M4^-(TOY.!/^AUM';04?(QA?F;&+,T3WLTC0#[NEW/FV4I;)=@Z1R5TD&SZ]_
M,ZLD6?@ 8VQC0+NQVT979>7QY%%9TL'OC6_GA^MK![^?UD_@7X+_.6B<-<Y/
M#P\VS;]P=C,Z?7#T_>0O<MWXZ_ST<ZXE_&"/E(K=@#2XQQ2Y8+?D2GC4M\P!
MBUPSR5LYN!%NO7SJ??O$H[+-_7P@NGL$+D\.-$40""\Z%K"[($]=WO;WB,W\
M@,G<X4>_J;K[!YN7RQM:\G8GR!T>'!V>WG5XDP=D=[=0.M@\.EPJ&2_(@;]#
M%?!6'WAP]NTKN;XZ_IP+O'*Y4JS4MIW2_]C=[FZ^Q+UVL53XN]O.D?IYXW/N
M12A]02;%0X.>'(NVSP,N?-+H,$F[+ RXK<@5ZPH9*#C(I4/^"*F$&];7RL5R
MF7SA/O5M3EVX2H5NH Z.KH!VZCOD4HH>=X#6HU!QGRE%?G0=&K#G:N H\5/-
M^D69FR?7OY]=G)*Z^T^'P2/E1ZE^A6)?K:\U)'+O]*X+/%,D$.0TE*++J$^N
M>0#$Y%^6[-,_?IR>3Z:[?DNEPQQ2=QRM.7#HXJQ.ODKJ!SB98^%U71:P%Y[&
M]QZ39*OX;R):*(EOWTZOR GSX#RGY)8''7+.;OOD2#B<P=RN@]#I1_ROVP'O
M ?VCE(^!FGWRU.EHLDEQLG;.=Y2#+]\O&O&CF]2^:4L1^D[>%JZ0>^2V W/.
M'5Z&TNY0Q:SUM8N_R$??H:JS3RY$CWE-T %-::EJ$0T!\>F#'Q, Q#(WG/EV
MX6#SQR'9N*#*H;_VR/'7QO]]LLA&T&'DH^N@8J&^4+__4>J_B)"#$]&CHU.?
MUM<"X= ^D1J=0 5;"11) T7 )4GPV8$&KE\&N CS46&O63=(S:92C&:#R-4U
MR.7 'R34F$5@2O@D.R;/6 %I1M!F$,]VN<]M(,!A/>:*+NH7/JP-!"F8._)^
M#/2]1CV*I/(360)&Y(<,K9TZ/1 !,EPR1BY1A4@Y80M(##%#$>[W&!#0IG!C
MFQPW2CLEPW@J&>E V.+VB2? ["C*M=G7K&>^+4))VW@+B(22EA0>@4,#MFM6
M4T\1JL@M<UW\MT5[0M*FRV*M6%_3-]H:F%!"5/8)[<*]U.X !YH,1^B&4H5F
M\"YC$FG65'#? =[)?B'64$6Y@ZI_SA4E5]P&!90.MX 6ID"'0 %P8L>GW[7J
M _PDB@P0FC*20JSH/Q&-<"B@2'69'>!-/J,R#\H;TZUM#(XS7PK7U7H&!!JP
MM@C3S@2HOW\:'SK1#2F$/$L3&TO4270W=;>!SO,C$MUPRX!C+@>%QY\H0 VZ
MR$,*K)-<.$BH KWC+9 2D')?7F@:$3-?RC1FBST2>F:"V!2>Q2)P&07F@P0X
M0HX5&89%N.9_&E,0V&B;Y25SM8DXK,U\T"7MJ1RN&!B>TK*$>R$$ WKA*C#0
M"(- .7OX')1I$U0:I05""L0=M]?7!,Q/>*CT<(?/(!SQ@0-!)U0HL0!4$J^'
M>\&Z%?,5U\,V)04J;3 [T.7KL!M;ETO:.AB@&"DH8[4X[@6-XH4S'_@8A BR
M+5+7]KT!,00 /&J3@B<!OD<C/JC^6D--O**54S/ W*056@\8:7CZ*0.[T/A4
M0.<5(STP<'W-%[>132$9J4%C!R/\ML!3,>*9IQDBN ]<O.X"<RS]X L&=TA7
M1WLQ@<?_,+N#<7;8=#EZR;?@(B"A2")_C8&QV9LT0.V-3P06.M5&_>C\%-#X
M_/RR?G)R=O'U<ZZ8TW]?7]:/X[]_GITT?O^<*Q6+_\XM)$P%YC2NXB=#:!H@
M7^))PXU8H#AHG#S(DEON!!UX6J&\Q?T<UD9.#I]Z3QJI<(+Y%O6XV]\CUWVO
M*5Q@G\<=1P3[2>SRZ""YP]).5+69\C\^,%+I4!O2'C\V9'"IL;>)[0C=CO:B
M.F#WA-0Q1Q.\C@/.;I]0\/CF06"L@%+,>1HAT</L5.#11[\+ 6/!S'RS<87_
MATJT6-/)]'5Y^AJK61>"%IMW : &\:F0%OD/1?:=%LA7ZO80Q;^=6*@K&.&A
M$QCQY(/P*/*]A 8#]&O$,?"X*.S$^&ZR<=RHGWQ"Q]5BDF%(C>$=I"-?).8X
MRA9X($[(,N5\L\IY:93,Q.(!$QZW3?8#*E6OGQV;I+7#7$=K5-B&&XW/<Y@'
M<5L@39)%B2-N?0S!B.KPEHZ7HD 1HTC6PQ"MR4$$\L:D.[8;8KBSOO;7?\_S
M54B/Z> \1DW<;[G4\W1096%4"Q$,1)LAF$4[-&'I.!V/1T43,A&ABX$M@']3
M,=DS=W48=8,.9!>^\/..CB,1S#%2A<0\!/NQTH$A)!HBBD(Y1&TF98K22I',
M$\EW1;N?8?G;-9=CJCI$AJ#H?0@" E/JT1$XQA0M+E5 .M1MH8* Y50MH^@*
M50<.4?*A7"A5OV%$D2YGIC(8+#1%47\ZUUBR4BTM@O^C0L;7^;/H_6U:$(@7
M8E[ <DS9TC4'C*E]+"O,4E6]A2B&?-@I5 A0Z&+>K?-K::H2'RJ%[>0$]_72
M4LFDX6">4H,WCFH>1;$,P4$L,%=P@Y"S-\- 5_BP NDGMX#+C-)QG=:;P)X'
MX%6ZX.&$[S,7J%"!LJ*B+QLN)*ZOQ9/.?,;;U?BONG3FF@*TXX$*F*@)7,(<
M=+Y:J([7^5*A%I_ R(;,1>=UELQ!DR%S,>1\I%YWGWQOM;@-%+N<-KD+1@ 7
MJA!S"0C$D"R8)C5%:61#$UC2XH%*&(#U;-%B2AF?V&+ $T<"BWS,D@<61R%F
M#""THW?&J%S6ALLQL(/A(T-3@;!O\DU]?7KH>+#,UMZNK5VP@+@""X)#.@R*
M .F*T8V.<!W,068P.DN;RH?:P+9P"?$#3&H741]R'["_@EYY(?YB:2D94JJ%
MW9@42].R4X"L9$#+8\I^3V-&]65R*/CHC<DM_\KG(;Z#%'*/7-(VVX<)_0JQ
MZ  Z3?+YJ GKX.3LSW'/+I7'Z'$-CS4%A,LR.7;D4ON&E,!(E'"Y P3<6X#)
M*_X/,U;TC!X/G-3!)I ZANHF@!0 #P-9PD!=/=7T0VMC'HJS2U.: H\TZ^\-
MF>+G)C+4\'!)0GVDTZD\5:?3S/1ET/QJH=FT[( K%QZ;*=X)1$!=./]A:P!Y
MF2]_NPJC:RUZ-15_@,O@/9"_'Z!#?3@HUMT6=Q#.!@S"V0_5E+O.%.;M*DQ=
MZ?:[29$;-0B"UWS8K:0CN%92>M.%.$4D\RC'E@;:H]R-X[96",J(#4%=WF60
MRK.D(>BM5N?J31&F%J#N==V]0'UN0:,\VE6(ZPXT:2O*JP""KO6U)A=="+$]
M:NL;J)OT=#"_#5<X\5*S@^MI8&S]D9J77N;P14]7 RRB/%QB]H3+[!!5+MTD
M'0#-S*Q&3&C,65^#@71(K.*N$PQML?0 E_1$J(CJ*[ -38;$A]$"^6F:JNQ0
M2KC8[0\USZ&ZW^\;BA<^L!EGI#$.BVL/+,DXHRVQ3=T22S9.SH\^&?X@GU)3
M!/Z&+I6IJ8*@-O"J^K>33WH"<8/8H--O?0T)/_AQF)@J<.2CXFV/[N?+,'D;
M4 )B$$\XN)8DI-(+_S!)$B\O00 ?=&YI'UC? 8>#3,+%'RX3P:I!+]0],O3U
MB;S6UW3[Z>C8F@<1R9)%J[VH:!ZS.]3GRD/$L<TR 0@&QH+GV4'4F(C:$8LM
MW5^8EDM*U];7DI@+TI0@5K^QG5T%\@V;'^@#UF^:OX#<A,'(NR9&=HB2-%HD
M! ET@J"K]C8W;5"1NP*8R":R^BT@!V2@D[KO #N_"(E.)7\NQ U:TG4 2H5L
M?S/(^=#\SPX;':YT#P.Z4U<7#[%/#ORJKG9HWKB&-]@=&C-'FT4$G!X#,S"M
M@UA0N92Z<09H ;4'E01"S[E!*M#.*\R[/6RGQ^M+N[M;!5+'CIW!HZ/Q8P,>
MIL\"U-!6!0;LI^^#Y\'%8+/:J%K4QF,R?84V>8-8Z=:-Y-+83H$"L_"GK,$2
M.&F"F?DB("[WN%Z(#H25?CI $C;]1G!LQW'QO89T.&-'/9GW>I;OM8J[% =&
M*!N20&HT72/&SLOD"):/>\(%@+CQQ:WI< Q]\UMR=0./!)R"8!)XJZ6BB="<
M!,04<#QBA9 1ISS:AVF$, K2"F?"05>]7CY!49KB,7:BVAW$U8@6TT6%L3VN
MNFA<;.DFE@@8T0&WPB"4;+HG8ED8M0"T0FB" <23IO 'V+2^=@9*@LFL374%
MNR]"#8*Z*QOLZH&;]>.9!(>I0EP*4W%S-C#&BCN_XT.XS6[XX"V$KO&Q];7X
MJ.J(T'6&KS7-:L-'41>&CU'N#1]2C-V,7 ;3PT:F@ V?L=/C#^@"M8#4?OAB
MXR%'Z)+B[S'DHNDRD,V802.W.S)M #<O=?F '!"WPT>'P+(=B'*4(A'HH,4=
MW302=[*GS@2Z\MLV#M6$8:#F1MAP6IL%X!U8.@8UD>XA(.@0HD.QTUDO79@;
M'] A%_D'^H\93#B &"-NC8DJWFV"'#5_:Y<>F8?NT8ZVE@RP!,(#O5$,[335
M?(\F2\'0$%YAM'ACBI6Z,P$W*XHPS2X98(+H1H%;@BZ3YP7,Z3)Z ]/"I:@D
ME#6[9%IC8#O9V:'")DY4+UD1/\0<$.^8"%%4J=#K1FBL+1FN-HU&8,< R!#C
M8XZGM<7 PZ\0E;_%]=X=9^@FI*')^B*&8% .*=P"^3(>^N[#'E)MD"R-;68K
MB9&L62U.1&O<!^ 9>@\<.N5!X&%[9NTKB 2B<39:FH.1%+I0IEMC-Z)L +OK
MV9V.,=N?HHX4S'CASWNW:P0&IW^K.0"8BA5H_#OH6 339OTD[0N1S@[O&I^N
M&ZI EZ0BJ1'QP>897KR7Y89!!@6F+OJ,J?T1RD,;_)QJA< >4-UH0U#: +0Z
M&PT'U7="T(@D>4$A0+S2[MSSB]'*/3?KD(-E>NR\B94E.1CM,3)M_DI[9YVH
MZ#@?9@4PH*-LD 1R#E*_KE%1E]^ +76$V; 2I1D"\I@63,YO1SJ)@7Q/-Z -
MXH/4M?%Y;558BAB9(0 =I@]MDPI0Y+FM*Q@NO=40%#T-A6-([0I H)C#.G?I
MZ,TVJ*JZ^QER5X5(8^S?>$?CWQDH.?8,6@D@Z&@GUCQ,2B/';P09@[(VZV3U
M.T*I%@\B01NZ& 0=87H3A6X.#/2\C,7=LF@L-J(G/-Y^I4_H%7?6QMTG'+,9
M#<^Q$ ?[RZ)DW.A3; PQCT=UT6$M%AD[NC@7\G9MTEW<8"OC:0Q:!O56C.]_
MGIWD2[OK:WH/%?9;1@ ^@%1M*0 3';00K3J VQ(QTX:)QILZ-*Y%P5@:VARF
M;,F;@_I#Y*RNX/H8BY+=9<8Q0.!KU E@+XQ:%:*BO!OO@%2HI\8OI2/PTSNC
M;;@3U^/:E17(7Q *F6!$HY*,W-1C+@WL6<5XJS$.J+KGJTS_@OEMA,>E'7KP
M!!^#7\E:KE'0"%D>\)ZHW$B;[LC7T: &>&'#S"SC$X< 6@<WDS ZZ C%8E<[
M8/U#83;FV%@6TGO<C(?4_164.'V?HF+$FP$-.<;6^@6=G:'PDYAZ5 =P=C .
M! @1>9#%H<;BOU:4NV-5"SE@S-\UBS(I+#9Y#,I"[WS $1-K'C-D'##@T' 5
M*Z!J,,@3*0KF5Z@+)\W^$"+IR3O"$ (AJ1Y5[U("SL9[8Q&S>EQ[^I&H^E[N
M.$CP$(JY[AO6VZ&0"!I)4M=[X4'H_+BO\P+C(^^IFD6,7@_K6!S#W7+=27+V
M8IG\G#<53K%87\X6ZQ>Q6#]S]67L(LB\7H/P\"B/M0%4%O+"D^7,_,DO@'BX
M#CAY]61%"?[AZRX[O1+O1MO<!NW9)S2@*]N:'=NVP1J8F4N[BF$J9'XE"Y&X
MPCH]<3EMS ^LG!I^YV*;'ZQ33H%E@ZE.7N*,Q68(;@J(0Z9A:1>W&?CM 7ZE
M<:IQDB+W^#OR\>)SKC;,Q F _61:QDV\H5_C\ T>U(% <D+SQS1\&3/1)Q+X
MCJ5P@:LW*R@$7$U_CMW-R!:7M4 ^&SJ %Z'"??3XQ@L=RNJ62I.NQ@V6>K?<
MI]50F_(RU0:;*E;5-E>$O\]@;>F9K,VXN@B%S;BZ"KHZM6,8%^?*=G.C7*Q:
MY<J.5=[:^C1?YS%H7A2^9J]N8;F^MY3\/5D,T<'TWC#WAF+&"8*>)L TKFR\
M0CYX8_1JSQGN?,*0V<2RB2UW8L\"CI\F09Z %C,#180&?AM?T:F70S) R":6
M36SU 6&*2"(.>G!D['XO8?M[4H2J[CRA!C4!/B9MIQ]F3%SW>E+5ZR'ASO#
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MJF71!U^^7S32:I=O48^[_;W'!M'7IM_H]9.A.)B3I\ -VF:)L\=(0!$1!BH
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M22FQ9W"=I_D>[-8F1^'>#;EA1B6"A4K=M'219;0(!CD..HW7#=<F 4(MXZ$
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M"+I IK5E(/EP9BNCN=E . >L9Y&!27B4US(S7G!](RP<[?>='7:%!]8;BZR
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M>"TR,#(R,3$Q,"YX<V102P$"% ,4    "  '0&Y5Y'U0^?\*  !LAP  %0
M            @ %G P  8V=T>"TR,#(R,3$Q,%]L86(N>&UL4$L! A0#%
M  @ !T!N51C8&*U3!P  NU@  !4              ( !F0X  &-G='@M,C R
M,C$Q,3!?<')E+GAM;%!+ 0(4 Q0    (  = ;E5T>T_"XQ8  .Y_   2
M          "  1\6  !T;3(R,S S-C=D,5\X:RYH=&U02P$"% ,4    "  '
M0&Y5DAI>^#;#  !%>00 %0              @ $R+0  =&TR,C,P,S8W9#%?
M97@Q+3$N:'1M4$L! A0#%     @ !T!N5<;.CD#@&0  Q?(  !8
M     ( !F_   '1M,C(S,#,V-V0Q7V5X.3DM,2YH=&U02P$"% ,4    "  '
M0&Y5@V:19=4*  "T*P  %@              @ &O"@$ =&TR,C,P,S8W9#%?
@97@Y.2TR+FAT;5!+!08     !P ' - !  "X%0$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
